

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Precision medicine in inflammatory bowel disease:... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-54/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-54" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Precision medicine in inflammatory bowel disease: concept, progress and challenges" />
    
            <meta name="og:title" content="F1000Research Article: Precision medicine in inflammatory bowel disease: concept, progress and challenges.">
            <meta name="og:description" content="Read the latest article version by Simon P. Borg-Bartolo, Ray Kiran Boyapati, Jack Satsangi, Rahul Kalla, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="23032">
            <meta name="article-id" content="20928">
            <meta name="dc.title" content="Precision medicine in inflammatory bowel disease: concept, progress and challenges">
            <meta name="dc.description" content="Crohn&rsquo;s disease and ulcerative colitis are increasingly prevalent, relapsing and remitting inflammatory bowel diseases (IBDs) with variable disease courses and complications. Their aetiology remains unclear but current evidence shows an increasingly complex pathophysiology broadly centring on the genome, exposome, microbiome and immunome. Our increased understanding of disease pathogenesis is providing an ever-expanding arsenal of therapeutic options, but these can be expensive and patients can lose response or never respond to certain therapies. Therefore, there is now a growing need to personalise therapies on the basis of the underlying disease biology and a desire to shift our approach from &ldquo;reactive&rdquo; management driven by disease complications to &ldquo;proactive&rdquo; care with an aim to prevent disease sequelae. Precision medicine is the tailoring of medical treatment to the individual patient, encompassing a multitude of data-driven (and multi-omic) approaches to foster accurate clinical decision-making. In IBD, precision medicine would have significant benefits, enabling timely therapy that is both effective and appropriate for the individual. In this review, we summarise some of the key areas of progress towards precision medicine, including predicting disease susceptibility and its course, personalising therapies in IBD and monitoring response to therapy. We also highlight some of the challenges to be overcome in order to deliver this approach.">
            <meta name="dc.subject" content="inflammatory bowel disease, precision medicine, biomarkers, genomics, prognosis, therapeutics, Crohn's disease, ulcerative colitis, microbiome">
            <meta name="dc.creator" content="Borg-Bartolo, Simon P.">
            <meta name="dc.creator" content="Boyapati, Ray Kiran">
            <meta name="dc.creator" content="Satsangi, Jack">
            <meta name="dc.creator" content="Kalla, Rahul">
            <meta name="dc.date" content="2020/01/28">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.20928.1">
            <meta name="dc.source" content="F1000Research 2020 9:54">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="inflammatory bowel disease">
            <meta name="prism.keyword" content="precision medicine">
            <meta name="prism.keyword" content="biomarkers">
            <meta name="prism.keyword" content="genomics">
            <meta name="prism.keyword" content="prognosis">
            <meta name="prism.keyword" content="therapeutics">
            <meta name="prism.keyword" content="Crohn's disease">
            <meta name="prism.keyword" content="ulcerative colitis">
            <meta name="prism.keyword" content="microbiome">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/01/28">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="54">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.20928.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-54">
            <meta name="citation_title" content="Precision medicine in inflammatory bowel disease: concept, progress and challenges">
            <meta name="citation_abstract" content="Crohn&rsquo;s disease and ulcerative colitis are increasingly prevalent, relapsing and remitting inflammatory bowel diseases (IBDs) with variable disease courses and complications. Their aetiology remains unclear but current evidence shows an increasingly complex pathophysiology broadly centring on the genome, exposome, microbiome and immunome. Our increased understanding of disease pathogenesis is providing an ever-expanding arsenal of therapeutic options, but these can be expensive and patients can lose response or never respond to certain therapies. Therefore, there is now a growing need to personalise therapies on the basis of the underlying disease biology and a desire to shift our approach from &ldquo;reactive&rdquo; management driven by disease complications to &ldquo;proactive&rdquo; care with an aim to prevent disease sequelae. Precision medicine is the tailoring of medical treatment to the individual patient, encompassing a multitude of data-driven (and multi-omic) approaches to foster accurate clinical decision-making. In IBD, precision medicine would have significant benefits, enabling timely therapy that is both effective and appropriate for the individual. In this review, we summarise some of the key areas of progress towards precision medicine, including predicting disease susceptibility and its course, personalising therapies in IBD and monitoring response to therapy. We also highlight some of the challenges to be overcome in order to deliver this approach.">
            <meta name="citation_description" content="Crohn&rsquo;s disease and ulcerative colitis are increasingly prevalent, relapsing and remitting inflammatory bowel diseases (IBDs) with variable disease courses and complications. Their aetiology remains unclear but current evidence shows an increasingly complex pathophysiology broadly centring on the genome, exposome, microbiome and immunome. Our increased understanding of disease pathogenesis is providing an ever-expanding arsenal of therapeutic options, but these can be expensive and patients can lose response or never respond to certain therapies. Therefore, there is now a growing need to personalise therapies on the basis of the underlying disease biology and a desire to shift our approach from &ldquo;reactive&rdquo; management driven by disease complications to &ldquo;proactive&rdquo; care with an aim to prevent disease sequelae. Precision medicine is the tailoring of medical treatment to the individual patient, encompassing a multitude of data-driven (and multi-omic) approaches to foster accurate clinical decision-making. In IBD, precision medicine would have significant benefits, enabling timely therapy that is both effective and appropriate for the individual. In this review, we summarise some of the key areas of progress towards precision medicine, including predicting disease susceptibility and its course, personalising therapies in IBD and monitoring response to therapy. We also highlight some of the challenges to be overcome in order to deliver this approach.">
            <meta name="citation_keywords" content="inflammatory bowel disease, precision medicine, biomarkers, genomics, prognosis, therapeutics, Crohn's disease, ulcerative colitis, microbiome">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Simon P. Borg-Bartolo">
            <meta name="citation_author_institution" content="Department of Gastroenterology, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK">
            <meta name="citation_author" content="Ray Kiran Boyapati">
            <meta name="citation_author_institution" content="Department of Gastroenterology, Monash Health, Clayton, Victoria, Australia">
            <meta name="citation_author_institution" content="Faculty of Medicine, Nursing &amp; Health Sciences, Monash University, Clayton, Victoria, Australia">
            <meta name="citation_author" content="Jack Satsangi">
            <meta name="citation_author_institution" content="Translational Gastroenterology Unit, Nuffield Department of Medicine, Experimental Medicine Division, University of Oxford, John Radcliffe Hospital, Oxford, UK">
            <meta name="citation_author" content="Rahul Kalla">
            <meta name="citation_author_institution" content="Department of Gastroenterology, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA, UK">
            <meta name="citation_publication_date" content="2020/01/28">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="54">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.20928.1">
            <meta name="citation_firstpage" content="54">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-54/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-54.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=23032 /> <input type=hidden id=articleId name=articleId value=20928 /> <input type=hidden id=xmlUrl value="/articles/9-54/v1/xml"/> <input type=hidden id=xmlFileName value="-9-54-v1.xml"> <input type=hidden id=article_uuid value=2df37b3e-f62b-4772-ab15-a0dfe5dd1704 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Precision medicine in inflammatory bowel disease: concept, progress and challenges"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.20928.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.20928.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-54"
  },
  "headline": "Precision medicine in inflammatory bowel disease: concept, progress and challenges",
  "datePublished": "2020-01-28T15:51:13",
  "dateModified": "2020-01-28T15:51:13",
  "author": [
    {
      "@type": "Person",
      "name": "Simon P. Borg-Bartolo"
    },    {
      "@type": "Person",
      "name": "Ray Kiran Boyapati"
    },    {
      "@type": "Person",
      "name": "Jack Satsangi"
    },    {
      "@type": "Person",
      "name": "Rahul Kalla"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Crohn&rsquo;s disease and ulcerative colitis are increasingly prevalent, relapsing and remitting inflammatory bowel diseases (IBDs) with variable disease courses and complications. Their aetiology remains unclear but current evidence shows an increasingly complex pathophysiology broadly centring on the genome, exposome, microbiome and immunome. Our increased understanding of disease pathogenesis is providing an ever-expanding arsenal of therapeutic options, but these can be expensive and patients can lose response or never respond to certain therapies. Therefore, there is now a growing need to personalise therapies on the basis of the underlying disease biology and a desire to shift our approach from &ldquo;reactive&rdquo; management driven by disease complications to &ldquo;proactive&rdquo; care with an aim to prevent disease sequelae. Precision medicine is the tailoring of medical treatment to the individual patient, encompassing a multitude of data-driven (and multi-omic) approaches to foster accurate clinical decision-making. In IBD, precision medicine would have significant benefits, enabling timely therapy that is both effective and appropriate for the individual. In this review, we summarise some of the key areas of progress towards precision medicine, including predicting disease susceptibility and its course, personalising therapies in IBD and monitoring response to therapy. We also highlight some of the challenges to be overcome in order to deliver this approach."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-54",
            "name": "Precision medicine in inflammatory bowel disease: concept, progress..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Precision medicine in inflammatory bowel disease: concept, progress... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=23032 data-id=20928 data-downloads="" data-views="" data-scholar="10.12688/f1000research.20928.1" data-recommended="" data-doi="10.12688/f1000research.20928.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-54/v1/pdf?article_uuid=2df37b3e-f62b-4772-ab15-a0dfe5dd1704" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-20928-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-20928-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-20928-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Borg-Bartolo SP, Boyapati RK, Satsangi J and Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):54 (<a class=new-orange href="https://doi.org/10.12688/f1000research.20928.1" target=_blank>https://doi.org/10.12688/f1000research.20928.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-20928-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=20928 id=track-article-signin-20928 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/20928?target=/articles/9-54">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=23032 /> <input name=articleId type=hidden value=20928 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Precision medicine in inflammatory bowel disease: concept, progress and challenges</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Simon P. Borg-Bartolo<a href="https://orcid.org/0000-0002-6968-9518" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6968-9518</div><sup>1</sup>,&nbsp;</span><span class="">Ray Kiran Boyapati<a href="https://orcid.org/0000-0001-9683-8411" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-9683-8411</div><sup>2,3</sup>,&nbsp;</span><span class="">Jack Satsangi<sup>4</sup>,&nbsp;</span><span class=""><a href="mailto:rahul.kalla@ed.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Rahul Kalla</span></a><sup>5</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Simon P. Borg-Bartolo<a href="http://orcid.org/0000-0002-6968-9518" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6968-9518</div><sup>1</sup>,&nbsp;</span><span class="">Ray Kiran Boyapati<a href="http://orcid.org/0000-0001-9683-8411" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-9683-8411</div><sup>2,3</sup>,&nbsp;</span><span class="">Jack Satsangi<sup>4</sup>,&nbsp;</span><span class=""><a href="mailto:rahul.kalla@ed.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Rahul Kalla</span></a><sup>5</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 28 Jan 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.20928.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Gastroenterology, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK<br/> <sup>2</sup> Department of Gastroenterology, Monash Health, Clayton, Victoria, Australia<br/> <sup>3</sup> Faculty of Medicine, Nursing &amp; Health Sciences, Monash University, Clayton, Victoria, Australia<br/> <sup>4</sup> Translational Gastroenterology Unit, Nuffield Department of Medicine, Experimental Medicine Division, University of Oxford, John Radcliffe Hospital, Oxford, UK<br/> <sup>5</sup> Department of Gastroenterology, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA, UK<br/> <p> <div class=margin-bottom> Simon P. Borg-Bartolo <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Ray Kiran Boyapati <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Jack Satsangi <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> <div class=margin-bottom> Rahul Kalla <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=62466-58676></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=62467-58677></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Crohn’s disease and ulcerative colitis are increasingly prevalent, relapsing and remitting inflammatory bowel diseases (IBDs) with variable disease courses and complications. Their aetiology remains unclear but current evidence shows an increasingly complex pathophysiology broadly centring on the genome, exposome, microbiome and immunome. Our increased understanding of disease pathogenesis is providing an ever-expanding arsenal of therapeutic options, but these can be expensive and patients can lose response or never respond to certain therapies. Therefore, there is now a growing need to personalise therapies on the basis of the underlying disease biology and a desire to shift our approach from “reactive” management driven by disease complications to “proactive” care with an aim to prevent disease sequelae. Precision medicine is the tailoring of medical treatment to the individual patient, encompassing a multitude of data-driven (and multi-omic) approaches to foster accurate clinical decision-making. In IBD, precision medicine would have significant benefits, enabling timely therapy that is both effective and appropriate for the individual. In this review, we summarise some of the key areas of progress towards precision medicine, including predicting disease susceptibility and its course, personalising therapies in IBD and monitoring response to therapy. We also highlight some of the challenges to be overcome in order to deliver this approach. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> inflammatory bowel disease, precision medicine, biomarkers, genomics, prognosis, therapeutics, Crohn's disease, ulcerative colitis, microbiome </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Rahul Kalla (<a href="mailto:rahul.kalla@ed.ac.uk">rahul.kalla@ed.ac.uk</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Rahul Kalla </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Borg-Bartolo SP <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Borg-Bartolo SP, Boyapati RK, Satsangi J and Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):54 (<a href="https://doi.org/10.12688/f1000research.20928.1" target=_blank>https://doi.org/10.12688/f1000research.20928.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 28 Jan 2020, <b>9</b>(F1000 Faculty Rev):54 (<a href="https://doi.org/10.12688/f1000research.20928.1" target=_blank>https://doi.org/10.12688/f1000research.20928.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 28 Jan 2020, <b>9</b>(F1000 Faculty Rev):54 (<a href="https://doi.org/10.12688/f1000research.20928.1" target=_blank>https://doi.org/10.12688/f1000research.20928.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d28576e204>Core tip</h2><p class="" id=d28576e207>Our current understanding of inflammatory bowel disease (IBD), whilst incomplete, suggests an increasingly complex pathophysiology. Increasing biologic and small-molecule therapeutic options are available, but loss of response is common. Precision medicine in IBD, with the aim of tailoring the right therapy to the right patient at the right time on the basis of an individual patient’s biology, is an aspiration. We summarise recent progress in the pursuit of precision medicine in IBD and highlight some of the challenges that remain. In the future, precision medicine in IBD has the potential to enable delivery of truly individualised IBD care.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28576e213>Introduction</h2><p class="" id=d28576e216>Crohn’s disease (CD) and ulcerative colitis (UC) are forms of idiopathic IBD that follow a relapsing and remitting course<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. The incidence and prevalence of IBD are increasing worldwide, particularly in newly industrialised countries<sup><a href="#ref-3">3</a>–<a href="#ref-5">5</a></sup>. The pathogenesis of IBD remains unclear, although it is increasingly evident that the pathophysiological factors leading to heterogenous IBD phenotypes are increasingly complex and interwoven<sup><a href="#ref-6">6</a></sup>. Broadly, it appears that aetiological factors concentrate around the genome<sup><a href="#ref-7">7</a></sup>, exposome<sup><a href="#ref-8">8</a></sup>, microbiome<sup><a href="#ref-9">9</a></sup> and immunome<sup><a href="#ref-10">10</a></sup>. Whilst many factors have been identified by studying each of these disciplines in isolation, a true understanding of an individual patient’s aetiological and pathogenic mechanisms, and thus therapeutic options, will arise only from an integrated approach<sup><a href="#ref-11">11</a></sup>.</p><p class="" id=d28576e258>A growing understanding of the immunopathophysiological mechanisms underlying the development of IBD has led to significant advances in the ability to treat IBD effectively<sup><a href="#ref-12">12</a>–<a href="#ref-15">15</a></sup>. In a relatively short time, we have progressed from “conventional treatment” using corticosteroids with or without immunomodulators to having an increasing array of biologic and small-molecule therapies in our medical arsenal<sup><a href="#ref-16">16</a></sup>. However, the associated costs of treating IBD are also increasing<sup><a href="#ref-17">17</a>–<a href="#ref-20">20</a></sup>. It is also becoming clear that the first biologic therapy (that is, the initial biologic therapy commenced in an individual patient) seems to be the most effective with a “dampened” response rate using second-line biologics<sup><a href="#ref-21">21</a></sup>. Although IBD clinicians embrace increasing therapeutic options for our patients, we also have a responsibility to ensure optimal and efficient use for each individual patient. The ability to predict response, relapse and side effects as well as optimise drug levels and early identification of loss of response is highly desirable<sup><a href="#ref-22">22</a></sup>. The development of biomarkers to enable targeted and effective individualised treatment is therefore necessary to allow selection of the right drug at the right time in the right patient<sup><a href="#ref-23">23</a></sup>.</p><p class="" id=d28576e292>So it is clear that a change of perspective is required to advance our understanding of IBD. IBD is a stochastic, heterogenous disease with complex aetiology and increasingly complex treatment options. Traditional research approaches focusing on isolated aspects of IBD aetiology or treatment, whilst necessary and highly informative, run the risk of oversimplification without an appreciation of complex aetiological and pharmacological associations<sup><a href="#ref-11">11</a></sup>. There is a growing need for a “multi-omic” approach where data from different disciplines regarding the same subject are integrated to advance our understanding of IBD immunopathogenesis, to identify new drug targets and to identify biomarkers to enable better detection and treatment of disease<sup><a href="#ref-24">24</a></sup>. By understanding the complex pathogenesis of IBD, we will be better able to practice precision medicine in which we can tailor medical therapy to the individual patient<sup><a href="#ref-25">25</a>,<a href="#ref-26">26</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28576e313>Pathogenesis of inflammatory bowel disease</h2><p class="" id=d28576e316>The exact pathogenesis of IBD remains enigmatic. Whilst it is understood that complex interactions between host and environment are pivotal, it is not yet clear exactly how these lead to the various disease phenotypes. It is beyond the scope of this article to provide an in-depth review of IBD pathogenesis, but we will summarise some of the key points.</p><div class=section><a name=d28576e319 class=n-a></a><h3 class=section-title>Genetics</h3><p class="" id=d28576e324>The observation that the risk of developing IBD is greater in people who have relatives with IBD suggests a genetic component<sup><a href="#ref-27">27</a>–<a href="#ref-29">29</a></sup>. Genome-wide association studies (GWASs) have facilitated the discovery of a large number of significant genetic risk loci, some of which are discussed later in this article<sup><a href="#ref-6">6</a>,<a href="#ref-30">30</a></sup>. Many loci are shared between UC and CD<sup><a href="#ref-31">31</a></sup> and may overlap with loci associated with other inflammatory diseases<sup><a href="#ref-32">32</a></sup>. Functional gene polymorphisms are known to impact on innate immunity, adaptive immunity and regulation of the intestinal barrier<sup><a href="#ref-33">33</a></sup>. Despite the advances in genetic understanding, only about 25% of IBD heritability can currently be explained<sup><a href="#ref-30">30</a></sup>.</p></div><div class=section><a name=d28576e359 class=n-a></a><h3 class=section-title>Environment</h3><p class="" id=d28576e364>The incidence and prevalence of IBD are highest in the Western world, but newly industrialised countries are also experiencing increases in the incidence and prevalence of IBD, and migrants to the Western world acquire the same risk of IBD as that of the native population<sup><a href="#ref-34">34</a></sup>. This occurs independently of ethnicity and seems to mirror the industrialisation and westernisation of populations<sup><a href="#ref-4">4</a></sup>. Early life events, pollution, and diet have all been implicated in the development of IBD<sup><a href="#ref-8">8</a></sup>.</p></div><div class=section><a name=d28576e380 class=n-a></a><h3 class=section-title>Microbiome</h3><p class="" id=d28576e385>The dysbiosis seen in IBD has been well described as being characterised by a reduced microbial diversity, expansion of facultative anaerobes and decreased numbers of obligate anaerobes<sup><a href="#ref-35">35</a></sup>. In the most comprehensive analysis carried out to date on the microbiome in IBD, longitudinal profiles of 132 subjects were developed, demonstrating disruptions in microbial transcription and metabolite pools as well as increases in temporal variability associated with disease activity<sup><a href="#ref-36">36</a></sup>. It remains unknown which of these observed changes are the cause or consequence of IBD and this remains an area of intense investigation.</p></div><div class=section><a name=d28576e398 class=n-a></a><h3 class=section-title>Immunome</h3><p class="" id=d28576e403>The gut is a crucial immunological interface that maintains immunological balance by appropriately recognising and tolerating commensal bacteria, food antigens and self-antigens (tolerogenic response) whilst identifying and acting against pathogenic organisms (immunogenic response)<sup><a href="#ref-6">6</a></sup>. Dysregulated immunological responses within the gut leading to imbalances in pro- and anti-inflammatory pathways involved in innate and adaptive immunity are thought to be pivotal in the development and persistence of inflammation in IBD<sup><a href="#ref-37">37</a></sup>. Impaired barrier function of the epithelium coupled with epithelial neutrophil accumulation, defective antigen clearance by macrophages and impaired conditioning of dendritic cells are all innate immune factors thought to contribute to the persistence of inflammation<sup><a href="#ref-10">10</a></sup>. Dendritic cells bridge the gap between innate and adaptive immunity by inducing tolerance or immunogenicity amongst T and B cells and therefore can be influential in mucosal homeostasis versus mucosal inflammation<sup><a href="#ref-38">38</a></sup>. The balance between effector T cells (T<sub>H</sub>1, T<sub>H</sub>2, T<sub>H</sub>17 and T<sub>H</sub>9) and regulatory T (T<sub>reg</sub>) cells is crucial to maintaining tolerance or promoting chronic inflammation<sup><a href="#ref-39">39</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28576e446>Concept of precision medicine and its relevance to inflammatory bowel disease</h2><p class="" id=d28576e449>Precision medicine refers to the “tailoring of medical treatment to the individual characteristics of each patient”<sup><a href="#ref-40">40</a></sup>. Whilst the concepts of personalised medicine and precision medicine are very similar, precision medicine also encompasses a multidisciplinary data-driven approach to foster better clinical decision-making through a clear understanding of the molecular basis of an individual’s disease<sup><a href="#ref-41">41</a></sup>. In 2015, the national Precision Medicine Initiative, a novel and ambitious plan to collect multi-omic data on over 1 million patients in a new national cohort in an attempt to accelerate understanding of diseases and their treatments, was announced in the US<sup><a href="#ref-42">42</a></sup>. This high-profile endorsement of precision medicine has served to ignite interest in and raise awareness of the concept.</p><p class="" id=d28576e464>Precision medicine in IBD is conceptually attractive. We know that patients with CD or UC can have a markedly variable disease course. In Norwegian cohorts followed up over 10 years, the IBSEN study group found that up to 53% of patients with CD developed stricturing or penetrating disease and that up to 19% of patients with UC required colectomy by 10 years<sup><a href="#ref-43">43</a>,<a href="#ref-44">44</a></sup>. Traditional “step-up” therapy risks undertreating those patients who are destined to develop complications, but “top-down” therapy risks overtreating patients who may have remained stable and complication-free on less expensive therapies and exposes those patients to unnecessary side effects. Many clinical parameters, such as serological markers, disease location, disease behaviour, age and lifestyle, have been found to be associated with disease severity<sup><a href="#ref-45">45</a>,<a href="#ref-46">46</a></sup>. However, none is reliable or specific enough to alter early IBD management. Therefore, the ability to predict aggressive disease behaviour, high risk of disease complications, or response to certain treatments at or near the time of diagnosis for individual patients currently remains elusive. Nonetheless, there are encouraging signs of progress. This review aims to summarise some of the key progress made to date in the pursuit of precision medicine in IBD and aims to outline some of the challenges that have yet to be overcome.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28576e484>Predicting disease susceptibility and clinical phenotype</h2><p class="" id=d28576e487>GWASs have provided important insights into the aetiology and development of IBD<sup><a href="#ref-30">30</a></sup>. To date, over 240 IBD susceptibility loci have been identified through this approach<sup><a href="#ref-47">47</a>–<a href="#ref-50">50</a></sup>. Some of the key biological processes uncovered by GWASs include epithelial barrier dysfunction, disruption of antimicrobial defences and immune dysregulation. Whilst GWASs have provided numerous avenues to explore, these have yet to filter through as clinically useful biomarkers to help predict disease and its phenotype.</p><p class="" id=d28576e501>Some GWAS associations have been associated with distinct clinical phenotypes. <i>NOD2/CARD15</i> is involved in pattern recognition receptor signalling in response to microbial stimuli and has been associated with an ileal fibrostenosing disease phenotype<sup><a href="#ref-51">51</a>–<a href="#ref-54">54</a></sup>. <i>NOD2/CARD15</i> has also been associated with the need for surgery and complicated disease course<sup><a href="#ref-55">55</a></sup>. <i>ATG16L1</i>, which implicates defective autophagy as an important part of CD development<sup><a href="#ref-56">56</a></sup>, has been associated with ileal disease<sup><a href="#ref-57">57</a></sup>, and another autophagy gene, <i>IGRM</i>, has been associated with penetrating disease<sup><a href="#ref-58">58</a></sup>. <i>IL23R</i>, which has become a successful therapeutic target in CD<sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup>, has also been previously linked to ileal CD<sup><a href="#ref-61">61</a></sup>. However, most of these individual genes have limited effect sizes, meaning that applicability on their own to the general population is limited. Recent insights into the genetics of IBD reveal distinct clinical phenotypes. Exploring the associations between genetic risk scores and IBD sub-phenotypes in 29,838 patients, the UK IBD Genetics Consortium (IBDGC) was able to redefine disease subtypes into ileal CD, colonic CD and UC<sup><a href="#ref-62">62</a></sup>.</p><p class="" id=d28576e559>Similarly, the microbiome may have a role to play in helping identify “high risk” individuals. In a study of new-onset IBD, Gevers <i>et al</i>. found ileal microbiome signatures to be predictive of CD, even in the absence of overt inflammation<sup><a href="#ref-63">63</a></sup>. It is likely that the microbial signature of IBD will vary depending on the clinical phenotype<sup><a href="#ref-64">64</a></sup> as well as environmental factors such as smoking and medication use. Longitudinal studies have suggested an ability to predict CD and UC phenotypes on the basis of the microbiome and an ability to distinguish patients with IBD from those with similar symptoms<sup><a href="#ref-65">65</a></sup>. In the future, there is the enticing possibility of generating “risk scores” for patients on the basis of their microbiome<sup><a href="#ref-66">66</a></sup>.</p><p class="" id=d28576e581>Despite this tremendous progress in genetics and the microbiome, screening for IBD in the clinic continues to rely on a combination of clinical symptoms and blood-based biomarkers. More recently, faecal calprotectin (FC) has emerged as a robust screening tool for those with suspected IBD. Studies have shown that FC has a pooled sensitivity and specificity of 0.93 (0.85–0.97) and 0.96 (0.79–0.99) respectively and a high negative predictive value (NPV) (0.96–0.98)<sup><a href="#ref-67">67</a>,<a href="#ref-68">68</a></sup>. FC now represents one of the core tests in clinical practice in the UK (and elsewhere) as a screening tool to identify those who require further tertiary-care investigations for suspected IBD<sup><a href="#ref-69">69</a></sup>. Despite its value, several practical issues reported in the literature appear to hinder its widespread clinical uptake. First, patient compliance with FC is often poor. A recent study showed that only one third of patients were compliant with FC testing, forgetfulness being the main reason for non-compliance<sup><a href="#ref-70">70</a></sup>. Two recent studies investigating the acceptability of FC in IBD found that sample collection was a major barrier to testing; blood testing was preferred over stool testing<sup><a href="#ref-71">71</a>,<a href="#ref-72">72</a></sup>. These “patient factors” pose a real challenge for clinicians in implementing FC testing in clinical care and hamper its clinical utility. FC also shows within-day variations, and the ideal time of sample collection is unclear<sup><a href="#ref-73">73</a>,<a href="#ref-74">74</a></sup>.</p><p class="" id=d28576e614>Researchers are beginning to explore novel blood-based diagnostic markers across multiple -omics platforms, including epigenetics, metabolomics and proteomics, and the results have been promising. Multicentre consortia such as IBD-Character, IBD-BIOM and Biocycle have been funded by the European Commission to develop novel biomarkers that can be transitioned into the clinic; each focuses on specific unmet needs in clinical practice. Whereas IBD-Character and IBD-BIOM have focussed on developing diagnostic and prognostic multi-omic markers in IBD, Biocycle explores innovative regimes for maintenance treatment in moderate to severe CD<sup><a href="#ref-75">75</a></sup>. These have yet to be translated to clinically useful biomarkers but offer a glimpse into the potential for an expanded repertoire to help diagnose IBD wherever it is suspected. However, multiple challenges exist: biomarkers should have key qualities such as being simple, easy to perform, minimally invasive, rapid and reproducible, and should consistently show high accuracy in predicting disease across several populations<sup><a href="#ref-76">76</a></sup>. These characteristics have yet to be ascertained amongst the biomarkers studied so far.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28576e629>Predicting disease course</h2><p class="" id=d28576e632>Historically, gastroenterologists have relied on the established clinical predictors of disease course (<a href="#T1">Table 1</a>) to help tailor management. Over time, we have progressed from relying on clinical predictors to using biomarkers to predict outcomes and tailor treatment algorithms based on disease course. Markers such as FC have been shown to be associated with the need for colectomy in UC<sup><a href="#ref-77">77</a></sup>. Similarly, in a recent retrospective study, FC was shown to predict progression in CD behaviour, hospitalisation for a flare and surgery<sup><a href="#ref-78">78</a></sup>. There are, however, conflicting reports on its prognostic utility<sup><a href="#ref-79">79</a></sup>. Furthermore, the reported prognostic performance of FC is similar to that of other non-specific blood markers such as C-reactive protein (CRP). It is clear that, despite the available predictors, accurate prognostication at the time of IBD diagnosis has yet to be achieved.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Clinical parameters that predict unfavourable inflammatory bowel disease course.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28576e661 class=n-a></a><thead><a name=d28576e663 class=n-a></a><tr><a name=d28576e665 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d28576e667 class=n-a></a>Disease</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28576e670 class=n-a></a>Time frame</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28576e673 class=n-a></a>Predictor of unfavourable course</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28576e676 class=n-a></a>References</th></tr></thead><tbody><a name=d28576e681 class=n-a></a><tr><a name=d28576e683 class=n-a></a><td align=left colspan=1 rowspan=9 valign=top><a name=d28576e685 class=n-a></a>Crohn’s disease</td><td align=left colspan=1 rowspan=5 valign=top><a name=d28576e688 class=n-a></a>Within 5 years of diagnosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e691 class=n-a></a>Age &lt; 40</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e694 class=n-a></a><a href="#ref-88">88</a></td></tr><tr><a name=d28576e699 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e701 class=n-a></a>Need for steroids in first flare</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e704 class=n-a></a><a href="#ref-88">88</a>,<a href="#ref-89">89</a></td></tr><tr><a name=d28576e712 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e714 class=n-a></a>Perianal disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e717 class=n-a></a><a href="#ref-88">88</a>,<a href="#ref-89">89</a></td></tr><tr><a name=d28576e725 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e727 class=n-a></a>Upper gastrointestinal lesions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e730 class=n-a></a><a href="#ref-90">90</a></td></tr><tr><a name=d28576e735 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e737 class=n-a></a>Ileocolonic lesions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e740 class=n-a></a><a href="#ref-91">91</a></td></tr><tr><a name=d28576e746 class=n-a></a><td align=left colspan=1 rowspan=4 valign=top><a name=d28576e748 class=n-a></a>Within 10 years of diagnosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e751 class=n-a></a>Age &lt; 40</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e754 class=n-a></a><a href="#ref-44">44</a>,<a href="#ref-92">92</a></td></tr><tr><a name=d28576e762 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e764 class=n-a></a>Upper gastrointestinal lesions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e767 class=n-a></a><a href="#ref-92">92</a></td></tr><tr><a name=d28576e772 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e774 class=n-a></a>Stricturing and penetrating behaviour</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e777 class=n-a></a><a href="#ref-44">44</a></td></tr><tr><a name=d28576e782 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e784 class=n-a></a>Terminal ileal lesions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e787 class=n-a></a><a href="#ref-44">44</a></td></tr><tr><a name=d28576e792 class=n-a></a><td align=left colspan=1 rowspan=7 valign=top><a name=d28576e794 class=n-a></a>Ulcerative colitis</td><td align=left colspan=1 rowspan=2 valign=top><a name=d28576e797 class=n-a></a>Within 5 years of diagnosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e800 class=n-a></a>Younger age</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e803 class=n-a></a><a href="#ref-90">90</a></td></tr><tr><a name=d28576e808 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e810 class=n-a></a>Female gender</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e813 class=n-a></a><a href="#ref-90">90</a></td></tr><tr><a name=d28576e819 class=n-a></a><td align=left colspan=1 rowspan=5 valign=top><a name=d28576e821 class=n-a></a>Within 10 years of diagnosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e824 class=n-a></a>Younger age</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e827 class=n-a></a><a href="#ref-93">93</a></td></tr><tr><a name=d28576e832 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e834 class=n-a></a>Female gender</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e837 class=n-a></a><a href="#ref-93">93</a></td></tr><tr><a name=d28576e842 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e844 class=n-a></a>Fewer systemic symptoms</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e847 class=n-a></a><a href="#ref-94">94</a></td></tr><tr><a name=d28576e852 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e854 class=n-a></a>Extensive colitis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e857 class=n-a></a><a href="#ref-43">43</a>,<a href="#ref-94">94</a>,<a href="#ref-95">95</a></td></tr><tr><a name=d28576e868 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e870 class=n-a></a>Non-smoking status</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28576e873 class=n-a></a><a href="#ref-93">93</a></td></tr></tbody></table></div><p class="" id=d28576e881>We are, however, beginning to unearth the molecular profiles that associate with disease progression in IBD. The seminal study by Lee <i>et al</i>.<sup><a href="#ref-80">80</a></sup>, who explored the CD8 T-cell transcriptomic profiles in newly diagnosed IBD, identified unique RNA signatures that were associated with the need for treatment escalation or surgery (or both) over time in both CD and UC. In their follow-on study, Biasci <i>et al</i>. developed a multi-gene signature predicting the need for escalation using original criteria in UC (hazard ratio [HR] 3.1, 95% confidence interval [CI] 1.25–7.72, <i>P</i> = 0.02) and CD (HR 2.7, 95% CI 1.32–5.34, <i>P</i> = 0.01)<sup><a href="#ref-81">81</a></sup>, although this profile differs from the original T-cell profile signature. Using the same criteria for escalation, the UK IBDGC identified four prognostic genetic loci: <i>FOXO3, XACT</i>, a region upstream of <i>IGFBP1</i> and the MHC region<sup><a href="#ref-82">82</a></sup>. These genes were distinct from those that predict CD susceptibility. The molecular architecture of disease course has been further defined beyond genetics at a methylome, glycome and proteome level. Studies have shown that patients with an aggressive disease course display unique circulating methylome and proteome signatures<sup><a href="#ref-83">83</a>–<a href="#ref-85">85</a></sup>, including markers such as serum calprotectin<sup><a href="#ref-79">79</a></sup>, that predict treatment escalation or surgery (or both) over time. Glycomic markers have previously been shown to be associated with IBD<sup><a href="#ref-86">86</a></sup> and more recently have shown the ability to predict treatment escalation<sup><a href="#ref-87">87</a></sup>. All of these studies have similar clinical criteria for escalation, based on step-up approach treatment algorithms. In clinical practice, tailoring early “top-down” therapies in those with disease progression while avoiding potent therapies in those with a benign disease course at diagnosis is a real unmet need. It has yet to be ascertained whether this approach will improve clinical outcomes.</p><p class="" id=d28576e935>Other equally relevant definitions of disease course are being studied by IBD consortia across populations. One such consortium is the Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn’s Disease (RISK) study<sup><a href="#ref-96">96</a></sup>. Defining aggressive disease course as a progression in CD behaviour to either penetrating or stricturing complications over time, this prospective inception cohort study identified unique multi-omic profiles that associate with disease progression. Ileal transcriptomic data showed that expression of inflammatory response to microbe signatures versus extracellular matrix upregulation signatures discriminated between later-penetrating versus stricturing complication development. The addition of ileal transcriptomic data to a clinical and serologically based competing-risk score improved the sensitivity and specificity of the score<sup><a href="#ref-96">96</a></sup>. The RISK study group has also shown that by integrating summary-level GWAS and expression quantitative trait loci with RNA-seq data, transcriptional risk scores can be generated which outperform genetic risk scores in identifying CD and are able to predict CD disease course over time<sup><a href="#ref-97">97</a></sup>. Randomised controlled trials (RCTs) are needed to determine whether early characterisation and therapy based on these profiles have the ability to alter disease course over time in paediatric CD.</p><p class="" id=d28576e951>Microbial populations may have a role in helping predict disease course, as illustrated by a study in post-operative recurrence in CD<sup><a href="#ref-98">98</a></sup>. Here, the authors demonstrated that a decreased population of <i>Faecalibacterium prausnitzii</i> in the resected ileum correlated with a higher rate of recurrence<sup><a href="#ref-98">98</a></sup>. In a study of paediatric CD, gut microbial signatures at the time of diagnosis were found to help predict 6-month steroid-free remission<sup><a href="#ref-99">99</a></sup>. These studies demonstrate conceptually the potential for microbiome signatures to provide clinicians with prognostic information to help inform treatment decisions, although longitudinal studies and further validation are required.</p><p class="" id=d28576e969>Understanding the progression of IBD at diagnosis using several distinct yet clinically important criteria at a multi-omic level will help personalise treatment algorithms based on biology rather than symptomatology with an aim to improve clinical outcomes over time. Empowering patients with this information at diagnosis may aid progress towards personalising care in IBD.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28576e975>Personalising therapies in inflammatory bowel disease</h2><p class="" id=d28576e978>The array of treatment options in IBD has grown dramatically over recent years, and a large number of therapies are in the pipeline<sup><a href="#ref-13">13</a></sup>. Ultimately, the goal of precision medicine is to enable preferential selection of a specific therapy based on an individual patient’s biology whilst individualising dosing to ensure that therapeutic effects are maintained and side effect risk minimised. In current clinical practice, use of therapeutic drug monitoring (TDM) “biomarkers” is well established in order to increase the chances of response and reduce risk of side effects. Despite this, it is clear that currently available TDM strategies do not completely mitigate against the risk of adverse events. Large multicentre trials such as CALM have reported an adverse event rate of up to 24 to 26% using current anti-tumour necrosis factor (anti-TNF) therapies<sup><a href="#ref-100">100</a></sup>.</p><p class="" id=d28576e989>In the case of thiopurines, we are able to predict the risk of life-threatening myelosuppression by measurement of thiopurine methyltransferase (TPMT) enabling dose reduction with intermediate and low levels at the point of treatment commencement<sup><a href="#ref-101">101</a></sup>. Until recently, NUDT15 polymorphisms were known to be associated with the onset of thiopurine-induced myelosuppression and were thought to be most relevant in Asian populations<sup><a href="#ref-102">102</a>,<a href="#ref-103">103</a></sup>. However, a recent multicentre, case control study of patients of European ancestry either affected or unaffected by thiopurine-induced myelosuppression has altered this perception<sup><a href="#ref-104">104</a></sup>. In that study, a GWAS and exome-wide association study (EWAS) approach identified an association between a NUDT15 variant and myelosuppression<sup><a href="#ref-104">104</a></sup>. Carriage of any three coding NUDT15 variants was associated with an increased risk of myelosuppression. The number needed to genotype was 95, at par with TPMT<sup><a href="#ref-104">104</a></sup>. These data suggest that there may be a role for NUDT15 sequencing in addition to TPMT sequencing prior to commencing thiopurines. HLA type has also been demonstrated to be a predictor of side effects in thiopurine therapy. In a multicentre study, 433 patients who had developed thiopurine-induced pancreatitis within 3 months of starting thiopurine therapy and case controls were identified. Using a GWAS approach, an association with pancreatitis development was found at rs2647047 which was found to link to HLA-DQA1 and HLA-DRB1 alleles. Compared with a baseline risk of about 4% for thiopurine-induced pancreatitis in all patients, those heterozygous for rs2647047 had a 9% risk and those who were homozygous had a 17% risk<sup><a href="#ref-105">105</a></sup>. During thiopurine therapy, thiopurine metabolites can be measured to determine whether a particular drug dose is optimised to produce a beneficial therapeutic effect whilst identifying poor compliance where it exists and minimising risks of side effects in an individual patient<sup><a href="#ref-106">106</a>,<a href="#ref-107">107</a></sup>.</p><p class="" id=d28576e1027>Similarly, TDM for biologic therapies is increasingly embedded in clinical practice. Anti-TNF therapy monitoring with measurement of trough drug levels and detection of anti-drug antibodies allows optimisation of therapeutic effect and directs decisions to switch biologic therapy in the case of primary and secondary non-response<sup><a href="#ref-108">108</a></sup>. In their RCT, Steenholdt <i>et al</i>. compared reactive TDM for anti-TNF therapy with empiric dose escalation in the setting of secondary loss of response<sup><a href="#ref-109">109</a></sup>. In that RCT, TDM was associated with significant cost reductions. In the TAXIT<sup><a href="#ref-110">110</a></sup> and Tailorix<sup><a href="#ref-111">111</a></sup> RCTs, anti-TNF dosing based on proactive TDM was compared with dosing based on clinical features. In the TAXIT trial, there was a significantly reduced relapse rate and modest cost saving in the proactive TDM group. By contrast, the Tailorix trial found that there was no significant benefit of proactive TDM over-dosing based on clinical features. Overall, anti-TNF TDM is associated with reduced cost and improved durability of response, but there is no conclusive evidence that a proactive or reactive approach is superior<sup><a href="#ref-112">112</a></sup>.</p><p class="" id=d28576e1054>Accurate pre-treatment prediction of response to biologic therapy would enable better drug selection for patients. Currently, there are no clinically available biomarkers that accurately predict treatment response, although a large number of potential candidates have been studied and extensively reviewed recently<sup><a href="#ref-26">26</a></sup>. Here, we report a number of new and noteworthy examples. West <i>et al</i>. demonstrated reproducibly in a number of data sets that high expression of oncostatin M (OSM) (a cytokine) is associated with reduced anti-TNF response<sup><a href="#ref-113">113</a></sup>. Verstockt <i>et al</i>. showed that low serum expression of Triggering Receptor Expressed on Myeloid cells 1 (TREM1) measured prior to commencing therapy is an accurate anti-TNF–specific marker for future anti-TNF response with endoscopic remission in both CD and UC<sup><a href="#ref-114">114</a></sup>. Telesco <i>et al</i>. identified and validated a 13-gene signature that predicted week 6 mucosal healing response (area under the curve receiver operating characteristics (AUC<sub>ROC</sub>) = 0.688, <i>P</i> = 0.002) to golimumab in the PURSUIT and PROgECT studies. The low specificity of this 13-gene signature may impact on the utility of this multi-gene panel<sup><a href="#ref-115">115</a></sup>. In a novel approach, Morilla <i>et al</i>. identified and validated a nine-microRNA signature in colonic biopsies in acute severe UC, successfully classifying responders and non-responders to corticosteroids, infliximab and cyclosporine in 90%, 84% and 80% of patients respectively<sup><a href="#ref-116">116</a></sup>.</p><p class="" id=d28576e1097>Prediction of response to biologic therapy using the microbial signatures of patients with IBD has also been a focus of recent investigation. Faecal microbial diversity resembled controls in paediatric patients who responded to anti-TNF therapy compared with non-responders<sup><a href="#ref-117">117</a></sup>. Similarly, Ananthakrishnan <i>et al</i>. found differences in the distal gut microbiome of CD patients who responded to anti-integrin therapy compared with non-responders<sup><a href="#ref-118">118</a></sup>. The authors reported higher abundance of <i>Roseburia inulinivorans</i> and a <i>Burkholderiales</i> species as well as enrichment of 13 microbial pathways in those achieving remission. Furthermore, a neural network algorithm was able to predict drug response, although, interestingly, these findings were not apparent in UC. For ustekinumab, using 16S rRNA gene sequencing, Doherty <i>et al</i>. reported that at week 6 into therapy, patients in remission could be distinguished from those with active disease by characterisation of their microbiome<sup><a href="#ref-119">119</a></sup>. Although these studies collectively show promise as proof of concept, large-scale validation is required before these tools can become part of clinical practice.</p><p class="" id=d28576e1125>Predicting treatment failure is equally important to potentially facilitate early switching of therapy and increase the likelihood and cost-effectiveness of recapturing response. Recently, results from the Personalised Anti-TNF Therapy in Crohn’s Disease Study (PANTS) were published<sup><a href="#ref-120">120</a></sup>. This multicentre, prospective, observational cohort study included 1610 patients from the point of first anti-TNF therapy exposure and followed them up for 12 months or until withdrawal of anti-TNF therapy. Low drug concentrations at week 14 were associated with primary non-response and non-remission at week 54. Obesity at baseline was associated with non-remission at week 54 for adalimumab only. Immunogenicity by week 54 was seen more commonly in patients on infliximab than on adalimumab (62.8% versus 28.5% respectively). Drug concentrations at week 14 were an independent risk factor for immunogenicity for both drugs. Obesity in the case of adalimumab and smoking in the case of infliximab were also associated with immunogenicity. Immunomodulator use was the main protective factor, and thiopurine-related reduction in immunogenicity occurred in a dose-dependent fashion. The PANTS study group has also presented data showing that HLA variants determine anti-TNF therapy immunogenicity and <i>HLA-DQ1*05</i> genotype was a key factor<sup><a href="#ref-121">121</a></sup>. Attention has also focussed on the role of glycosylation. This complex post-translational modification of proteins affects their function and can be significantly altered in inflammation<sup><a href="#ref-91">91</a></sup>. Pereira <i>et al</i>. recently demonstrated that lower levels of branched N-glycans in colonic biopsies from a cohort of 131 patients with UC were predictive of failure to respond to standard therapy (5-ASA, corticosteroids and immunomodulators)<sup><a href="#ref-122">122</a></sup>. The authors also demonstrated that the sensitivity and specificity of the predictive effect were different at time of diagnosis, within 5 months of diagnosis, and at time of diagnosis in patients presenting with severe disease. The only other independent predictor of failure of standard therapy was demonstrated to be high CRP. When low levels of branched N-glycans and high CRP levels were combined in all UC versus severe UC patients at the time of diagnosis, the probability of failure of standard therapy was 46.6% versus 76.5% respectively, sensitivity was 69% versus 88% respectively, and specificity was 80% versus 75%<sup><a href="#ref-122">122</a></sup>.</p><p class="" id=d28576e1155>More recent studies have used single-cell gene expression technologies in order to better understand the molecular pathophysiology of drug response. In active UC, there appears to be a differential reduction in epithelial mitochondrial genes in active UC, including the known master regulator of mitochondria biogenesis <i>PPARGC1A</i> (<i>PGC1α</i>) and epithelial mitochondrial membrane potential (<i>MMP</i>)<sup><a href="#ref-123">123</a></sup>. Intestinal epithelial depletion of <i>PGC1α</i> has been shown to negatively impact on mitochondrial function and subsequent epithelial barrier; barrier dysfunction is a feature of UC pathogenesis<sup><a href="#ref-124">124</a></sup>. This study also identified a gene signature that associates with anti-TNF and anti-integrin therapy response<sup><a href="#ref-123">123</a></sup>. In CD, a recent study investigating cellular subsets in ileal CD identified a unique cellular module in inflamed tissue that includes IgG plasma cells, mononuclear phagocytes, activated T cells and stromal cells (GIMATS module)<sup><a href="#ref-125">125</a></sup>. The presence of this module in patients at diagnosis was associated with a failure to achieve durable corticosteroid remission with anti-TNF therapy<sup><a href="#ref-125">125</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28576e1194>Monitoring response to therapy</h2><p class="" id=d28576e1197>Disease monitoring and “treat to target” (that is, using predefined outcome measures, such as clinical or endoscopic remission, as goals for the optimisation of therapy) are increasingly being recognised as a “gold standard” in IBD care. Mucosal healing is now considered a robust target and a clinical end-point for more recent drug trials<sup><a href="#ref-126">126</a>,<a href="#ref-127">127</a></sup>. In CD, the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) programme set out guidelines for the “treat to target” approach in order to obtain clinical and endoscopic remission<sup><a href="#ref-128">128</a></sup>. STRIDE recommended the use of FC and CRP to monitor response; however, until recently, there was no consensus on how to use these markers to adjust therapies. Following this, the CALM trial tested the efficacy of tight control management using 3-monthly biomarkers versus conventional management using Crohn’s Disease Activity Index on clinical and endoscopic outcomes in moderate to severe CD<sup><a href="#ref-100">100</a></sup>. Significantly higher numbers of patients achieved mucosal healing in the “tight control” arm compared with the conventional group. Furthermore, follow-up data from this study showed that patients with disease monitoring using biomarkers and a goal of achieving mucosal healing in the first year of treatment were less likely to have disease progression over a median of 3 years<sup><a href="#ref-129">129</a></sup>.</p><p class="" id=d28576e1219>Monitoring response to therapy has been studied using conventional biomarkers such as FC and CRP. Heida <i>et al</i>., in a systematic analysis of six studies, showed that two consecutive elevated FC predicted disease relapse within the following 2 to 3 months<sup><a href="#ref-130">130</a></sup>. However, the study was not able to define an optimal FC cutoff for monitoring. An FC cutoff of not more than 250 μg/g was shown to predict endoscopic remission (positive predictive value 48.5% and NPV 96.6%)<sup><a href="#ref-131">131</a></sup>. Similarly, CRP has been shown to correlate with clinical disease activity and endoscopic inflammation. However, CRP is a non-specific inflammatory marker and can often be raised in other clinical scenarios such as infections. Furthermore, some patients with active disease can have normal CRP levels<sup><a href="#ref-132">132</a></sup>.</p><p class="" id=d28576e1237>An area of intense interest is how best to monitor response with therapeutic de-escalation<sup><a href="#ref-133">133</a></sup>. The most robust study of anti-TNF de-escalation was the STORI trial, in which Louis <i>et al</i>. prospectively followed 115 patients with CD on combination therapy who discontinued the anti-TNF after at least 6 months of corticosteroid-free clinical remission<sup><a href="#ref-134">134</a></sup>. The investigators found that those who experienced a relapse and those who did not had different evolution of CRP and FC with a marked and sudden rise in these biomarkers 4 months prior to relapse<sup><a href="#ref-135">135</a></sup>. Several studies have explored other biomarkers of response and, in particular, mucosal healing. In a study looking at blood transcriptional biomarkers, initial whole blood microarray analysis was performed by using Affymetrix GeneChip technology to identify changes in transcriptional gene expression in endoscopically active UC compared with normal controls<sup><a href="#ref-136">136</a></sup>. After quantitative reverse transcription polymerase chain reaction (RT-PCR) validation, transcription of neutrophil-related genes, including <i>CD177</i>, <i>haptoglobin</i>, <i>G protein–coupled receptor 84</i>, and <i>S100 calcium-binding protein A12</i>, were demonstrated to be most associated with endoscopic disease activity. The above factors were also shown to decrease in association with a reduction in endoscopic disease activity after 14 weeks of anti-TNF treatment in a further group of patients with UC.</p><p class="" id=d28576e1272>Glycoprotein acetylation (GlycA) is another example of a novel biomarker. In a prospective pilot study of patients with IBD, serum GlycA levels were measured via high-throughput nuclear magnetic resonance spectroscopy to investigate its role as a disease activity biomarker. GlycA was shown to normalise to healthy control levels in patients achieving mucosal healing and to significantly decrease in patients who had evidence of improvements in endoscopic appearances regardless of the treatment used. GlycA was also shown to be a useful marker of response in patients with normal CRP levels at baseline. When compared with FC and CRP, GlycA was the only marker to show consistent significant differences between responders and non-responders regardless of the treatment given. GlycA may have advantages over CRP as it is a composite marker originating from a number of acute-phase proteins and so is more stable than CRP. The cost of GlycA measurement was reported to be comparable to that of FC<sup><a href="#ref-137">137</a></sup>.</p><p class="" id=d28576e1280>A number of studies have also investigated the applicability of faecal immunochemical testing (FIT) to assess disease activity and mucosal healing in UC. In a recent systematic review, the pooled sensitivity and specificity of FIT to predict mucosal healing were found to be 0.77 (95% CI 0.72–0.81) and 0.81 (95% CI 0.76–0.85) respectively, which were similar to previously published sensitivities and specificities of FC in predicting mucosal healing<sup><a href="#ref-138">138</a></sup>. In a study comparing sequential FIT and FC measurements in 84 UC patients having more than one colonoscopy over a 33-month period, the accuracy of assessment of disease activity and mucosal healing was studied<sup><a href="#ref-139">139</a></sup>. Where the previous colonoscopy and faecal markers had previously demonstrated mucosal healing, there was increased accuracy of FIT versus FC in predicting mucosal healing at the next colonoscopy. Where the previous colonoscopy and faecal markers had previously shown active inflammation, there was again increased accuracy of FIT versus FC in predicting mucosal healing at the next colonoscopy. However, where there was inflammation seen on both colonoscopies, FC better reflected changes in endoscopic activity than FIT. This interesting study suggests that FIT and FC provide slightly different information in disease monitoring in UC and that measuring both may be of benefit.</p><p class="" id=d28576e1291>Given the well-characterised changes in the microbiome of patients with IBD, restoration of the microbial diversity of patients has been explored as a potential biomarker to assess response to therapy. Restoration of gut microbial diversity has been seen in response to anti-TNF therapy<sup><a href="#ref-140">140</a></sup>. In a study of paediatric IBD, Shaw <i>et al</i>. found that dysbiosis was correlated with inflammatory burden and that in UC, but not in CD, improvements in faecal diversity correlated with clinical response<sup><a href="#ref-141">141</a></sup>.</p><p class="" id=d28576e1305>When taken together, the above studies demonstrate the potential utility of traditional and novel biomarkers as surrogates for endoscopic healing and indicators of pre-clinical relapse. Currently, it seems clear that a combination of clinically available biomarkers should be used to monitor disease activity and response to therapy. There is, however, a need for novel specific biomarkers to translate to clinical practice.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28576e1311>Future challenges and horizon of precision medicine in inflammatory bowel disease</h2><p class="" id=d28576e1314>Substantial progress has been made in our ability to treat CD and UC. With the increasing array of treatment options available, the need for precision medicine in IBD as a whole is paramount. Currently available biomarkers have improved our ability to assess and monitor disease activity and therapeutic efficacy, but each has its own limitations. The aim of precision medicine in IBD is to deliver truly individualised care so that the entire patient journey from diagnosis to treatment is based on the specific biology underlying IBD in the individual patient. The current progress towards precision medicine and likely complex inter-relationships of these multi-omic data in IBD are depicted in <a href="#f1">Figure 1</a>. Whilst there has been progress, there is still a significant path ahead before precision medicine is achieved in IBD. Our proposed pathway to precision medicine in IBD is shown in <a href="#f2">Figure 2</a>. As our understanding improves, through using current and novel biomarkers, we will be able to better predict and stratify disease which will positively feedback into an improved ability to identify areas for further biomarker and therapeutic development. This iterative approach will increase our ability to precisely target an individual patient’s inflammation on the basis of their molecular profile, allowing matching of the patient to the most appropriate therapy and monitoring. The overall aim will be to eventually achieve cure rather than simply mucosal or histological healing.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/23032/a33a505e-e5ec-405a-a316-15ba40db0ae2_figure1.gif"><img alt="a33a505e-e5ec-405a-a316-15ba40db0ae2_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/23032/a33a505e-e5ec-405a-a316-15ba40db0ae2_figure1.gif"></a><div class=caption><h3>Figure 1. Current progress towards precision medicine in inflammatory bowel disease.</h3><p id=d28576e1333>This figure summarises some of the progress that has been made towards precision medicine in inflammatory bowel disease and the likely complex inter-relationship of multi-omic data.</p></div></div><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/23032/a33a505e-e5ec-405a-a316-15ba40db0ae2_figure2.gif"><img alt="a33a505e-e5ec-405a-a316-15ba40db0ae2_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/23032/a33a505e-e5ec-405a-a316-15ba40db0ae2_figure2.gif"></a><div class=caption><h3>Figure 2. The evolution of precision medicine in inflammatory bowel disease.</h3><p id=d28576e1350>CRP, C-reactive protein; TPMT, thiopurine methyltransferase.</p></div></div><p class="" id=d28576e1357>There remain many challenges in order to deliver effective precision medicine in IBD. With the need to look towards big data approaches to make progress in biomarker discovery and improving outcomes in IBD, new approaches to high-quality data sharing are required<sup><a href="#ref-24">24</a></sup>. This will require infrastructural changes involving sharing of data between research groups and eventually involving the use of electronic health records. The eventual goal would be to have electronic health records that are able to integrate seamlessly with large clinical and research databases to facilitate early adoption of advances in knowledge whilst providing real-time, up-to-date support to clinicians in making decisions regarding their patients<sup><a href="#ref-142">142</a></sup>. There will also need to be new approaches to how data are analysed to maximise their effect. With large amounts of data, there will be an increasing reliance on complex algorithms, including the use of machine learning to make sense of big data coming from multiple sources<sup><a href="#ref-143">143</a>,<a href="#ref-144">144</a></sup>. However, there must be stringent checks to ensure that the quality of the data is maintained and that the hypotheses generated are subjected to rigorous validation through pre-clinical and real-world trials prior to adoption in wider medical practice<sup><a href="#ref-24">24</a></sup>. One of the biggest barriers to precision medicine in IBD is the lack of a clearly defined mechanism (or mechanisms) of disease<sup><a href="#ref-145">145</a></sup>. As we discover new biomarkers and learn new ways of practicing medicine in IBD more precisely, we must use these to interrogate the existing understanding and challenge existing pathophysiological models.</p><p class="" id=d28576e1384>However, there are grounds for significant optimism. A number of ongoing studies will advance our understanding of precision medicine in IBD. The Predicting outcomes For Crohn’s disease using a molecular biomarker (PROFILE) trial (ISRCTN11808228) is the first biomarker-stratified trial in IBD<sup><a href="#ref-146">146</a></sup>. It is currently recruiting and aims to recruit 400 patients from about 50 centres across the UK. In that trial, a gene expression signature previously found to determine more aggressive disease<sup><a href="#ref-80">80</a></sup> will be tested for by means of a whole blood quantitative polymerase chain reaction assay that has been previously validated<sup><a href="#ref-147">147</a></sup>. Trial participants in each biomarker group will be randomly assigned 1:1 to receive accelerated step-up therapy or top-down therapy. The primary outcome measure for that trial will be sustained surgery and steroid-free remission, and one of the secondary outcome measures will be mucosal healing. The PRognostic effect of Environmental factors in Crohn’s and Colitis (PREdiCCt) Study (ISRCTN67248113) is also currently recruiting and aims to recruit a total of 3100 patients with CD or UC in remission. The study aims to follow these patients over two years and will collect information on diet, lifestyle and gut bacteria to see how these are associated with IBD flare and recovery.</p><p class="" id=d28576e1399>Following the efforts of several consortia to generate multi-omic datasets, there is now a need to define the IBD “interactome”: a disease network where perturbations in individual -omes cause intestinal inflammation, mediated by dysfunctional molecular modules<sup><a href="#ref-11">11</a></sup>. There are now several systems biology software tools that facilitate multi-level data integration such as iCluster<sup><a href="#ref-148">148</a></sup> that identifies patient subtypes within IBD on the basis of multi-omic high-throughput data while other tools allow visualisation of the interactome such as Cytoscape<sup><a href="#ref-149">149</a></sup>. Methodologies that facilitate data integration are comprehensively summarised in a recent review<sup><a href="#ref-11">11</a></sup>. Future drug innovations based primarily on IBD network interactions will transform the field of therapeutics in IBD<sup><a href="#ref-11">11</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28576e1425>Conclusions</h2><p class="" id=d28576e1428>Significant progress has been made towards the goal of precision medicine in IBD, but clearly there is still a substantial unmet need for further biomarkers with which to stratify patients and their treatment. It is vital that we continue to develop existing practice by assimilating advances in knowledge whilst optimising novel and existing biomarkers to continually make advances towards truly individualised care. Precision medicine in IBD will require not only the knowledge but the tools and the infrastructure with which to implement it effectively. This will require coordinated investment in technology to enable seamless sharing of big data and the ability to perform high-throughput analysis to create a continually learning IBD community. The recent announcement of the HDRUK G.I. Know Health Data Research Hub for IBD across the UK means that positive steps are already being taken towards integrated big data discovery to advance the field of precision medicine in IBD (<a target=xrefwindow href="https://www.hdruk.ac.uk/infrastructure/the-hubs/g-i-know/" id=d28576e1430>https://www.hdruk.ac.uk/infrastructure/the-hubs/g-i-know/</a>). Precision medicine has huge potential to impact on outcomes in IBD. We all have a responsibility to play our part in practicing high-quality biomarker-driven IBD care whilst contributing to big data in IBD so that in the future we will be able to offer truly individualised IBD care.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d28576e1 class=n-a></a><h2 class=main-title id=d29035>Author contributions</h2><p class=metadata-entry><a name=d28576e147 class=n-a></a><p id=d28576e148> Drafting of this review was performed by SB-B, RKB and RK. All authors contributed equally in the conception and design of this review, literature review and critical revision and editing, and final approval of the final version.</p></p></div><div class=back-section><a name=d28576e1438 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d29543>References</h2><div class="section ref-list"><a name=d28576e1438 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d28576e1445 class=n-a></a>Torres J, Mehandru S, Colombel JF, <i> et al.</i>: Crohn's disease. <i>Lancet.</i> 2017; <b>389</b>(10080): 1741–55. <a target=xrefwindow id=d28576e1456 href="http://www.ncbi.nlm.nih.gov/pubmed/27914655">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1459 href="https://doi.org/10.1016/S0140-6736(16)31711-1">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d28576e1468 class=n-a></a>Ungaro R, Mehandru S, Allen PB, <i> et al.</i>: Ulcerative colitis. <i>Lancet.</i> 2017; <b>389</b>(10080): 1756–70. <a target=xrefwindow id=d28576e1479 href="http://www.ncbi.nlm.nih.gov/pubmed/27914657">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1482 href="https://doi.org/10.1016/S0140-6736(16)32126-2">Publisher Full Text </a> | <a target=xrefwindow id=d28576e1486 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6487890">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725717456"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e1495 class=n-a></a>Molodecky NA, Soon IS, Rabi DM, <i> et al.</i>: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. <i>Gastroenterology.</i> 2012; <b>142</b>(1): 46–54.e42; quiz e30. <a target=xrefwindow id=d28576e1506 href="http://www.ncbi.nlm.nih.gov/pubmed/22001864">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1509 href="https://doi.org/10.1053/j.gastro.2011.10.001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725717456">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d28576e1522 class=n-a></a>Ng SC, Shi HY, Hamidi N, <i> et al.</i>: Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. <i>Lancet.</i> 2018; <b>390</b>(10114): 2769–78. <a target=xrefwindow id=d28576e1533 href="http://www.ncbi.nlm.nih.gov/pubmed/29050646">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1536 href="https://doi.org/10.1016/S0140-6736(17)32448-0">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d28576e1545 class=n-a></a>Sýkora J, Pomahačová R, Kreslová M, <i> et al.</i>: Current global trends in the incidence of pediatric-onset inflammatory bowel disease. <i>World J Gastroenterol.</i> 2018; <b>24</b>(25): 2741–63. <a target=xrefwindow id=d28576e1556 href="http://www.ncbi.nlm.nih.gov/pubmed/29991879">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1559 href="https://doi.org/10.3748/wjg.v24.i25.2741">Publisher Full Text </a> | <a target=xrefwindow id=d28576e1563 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6034144">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1091829"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e1573 class=n-a></a>Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. <i>Nature.</i> 2007; <b>448</b>(7152): 427–34. <a target=xrefwindow id=d28576e1581 href="http://www.ncbi.nlm.nih.gov/pubmed/17653185">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1584 href="https://doi.org/10.1038/nature06005">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1091829">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d28576e1597 class=n-a></a>Verstockt B, Smith KG, Lee JC: Genome-wide association studies in Crohn's disease: Past, present and future. <i>Clin Transl Immunology.</i> 2018; <b>7</b>(1): e1001. <a target=xrefwindow id=d28576e1605 href="http://www.ncbi.nlm.nih.gov/pubmed/29484179">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1608 href="https://doi.org/10.1002/cti2.1001">Publisher Full Text </a> | <a target=xrefwindow id=d28576e1611 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5822399">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d28576e1620 class=n-a></a>Ananthakrishnan AN, Bernstein CN, Iliopoulos D, <i> et al.</i>: Environmental triggers in IBD: a review of progress and evidence. <i>Nat Rev Gastroenterol Hepatol.</i> 2018; <b>15</b>(1): 39–49. <a target=xrefwindow id=d28576e1631 href="http://www.ncbi.nlm.nih.gov/pubmed/29018271">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1634 href="https://doi.org/10.1038/nrgastro.2017.136">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d28576e1643 class=n-a></a>McIlroy J, Ianiro G, Mukhopadhya I, <i> et al.</i>: Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. <i>Aliment Pharmacol Ther.</i> 2018; <b>47</b>(1): 26–42. <a target=xrefwindow id=d28576e1654 href="http://www.ncbi.nlm.nih.gov/pubmed/29034981">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1657 href="https://doi.org/10.1111/apt.14384">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d28576e1666 class=n-a></a>de Souza HS, Fiocchi C: Immunopathogenesis of IBD: current state of the art. <i>Nat Rev Gastroenterol Hepatol.</i> 2016; <b>13</b>(1): 13–27. <a target=xrefwindow id=d28576e1674 href="http://www.ncbi.nlm.nih.gov/pubmed/26627550">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1677 href="https://doi.org/10.1038/nrgastro.2015.186">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729084299"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e1686 class=n-a></a>de Souza HSP, Fiocchi C, Iliopoulos D: The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. <i>Nat Rev Gastroenterol Hepatol.</i> 2017; <b>14</b>(12): 739–49. <a target=xrefwindow id=d28576e1694 href="http://www.ncbi.nlm.nih.gov/pubmed/28831186">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1697 href="https://doi.org/10.1038/nrgastro.2017.110">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729084299">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d28576e1711 class=n-a></a>Paramsothy S, Rosenstein AK, Mehandru S, <i> et al.</i>: The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. <i>Mucosal Immunol.</i> 2018; <b>11</b>(6): 1558–70. <a target=xrefwindow id=d28576e1722 href="http://www.ncbi.nlm.nih.gov/pubmed/29907872">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1725 href="https://doi.org/10.1038/s41385-018-0050-3">Publisher Full Text </a> | <a target=xrefwindow id=d28576e1729 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6279599">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d28576e1738 class=n-a></a>Weisshof R, El Jurdi K, Zmeter N, <i> et al.</i>: Emerging Therapies for Inflammatory Bowel Disease. <i>Adv Ther.</i> 2018; <b>35</b>(11): 1746–62. <a target=xrefwindow id=d28576e1749 href="http://www.ncbi.nlm.nih.gov/pubmed/30374806">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1752 href="https://doi.org/10.1007/s12325-018-0795-9">Publisher Full Text </a> | <a target=xrefwindow id=d28576e1756 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6224002">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d28576e1765 class=n-a></a>Verstockt B, Ferrante M, Vermeire S, <i> et al.</i>: New treatment options for inflammatory bowel diseases. <i>J Gastroenterol.</i> 2018; <b>53</b>(5): 585–90. <a target=xrefwindow id=d28576e1776 href="http://www.ncbi.nlm.nih.gov/pubmed/29556726">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1779 href="https://doi.org/10.1007/s00535-018-1449-z">Publisher Full Text </a> | <a target=xrefwindow id=d28576e1783 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5910475">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d28576e1792 class=n-a></a>Odes S: How expensive is inflammatory bowel disease? A critical analysis. <i>World J Gastroenterol.</i> 2008; <b>14</b>(43): 6641–7. <a target=xrefwindow id=d28576e1800 href="http://www.ncbi.nlm.nih.gov/pubmed/19034966">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1803 href="https://doi.org/10.3748/wjg.14.6641">Publisher Full Text </a> | <a target=xrefwindow id=d28576e1806 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2773305">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d28576e1815 class=n-a></a>Reinglas J, Gonczi L, Kurt Z, <i> et al.</i>: Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. <i>World J Gastroenterol.</i> 2018; <b>24</b>(32): 3567–82. <a target=xrefwindow id=d28576e1826 href="http://www.ncbi.nlm.nih.gov/pubmed/30166855">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1829 href="https://doi.org/10.3748/wjg.v24.i32.3567">Publisher Full Text </a> | <a target=xrefwindow id=d28576e1833 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6113721">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d28576e1842 class=n-a></a>Burisch J, Jess T, Martinato M, <i> et al.</i>: The burden of inflammatory bowel disease in Europe. <i>J Crohns Colitis.</i> 2013; <b>7</b>(4): 322–37. <a target=xrefwindow id=d28576e1853 href="http://www.ncbi.nlm.nih.gov/pubmed/23395397">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1856 href="https://doi.org/10.1016/j.crohns.2013.01.010">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d28576e1866 class=n-a></a>Bähler C, Vavricka SR, Schoepfer AM, <i> et al.</i>: Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014. <i>BMC Gastroenterol.</i> 2017; <b>17</b>(1): 138. <a target=xrefwindow id=d28576e1877 href="http://www.ncbi.nlm.nih.gov/pubmed/29197335">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1880 href="https://doi.org/10.1186/s12876-017-0681-y">Publisher Full Text </a> | <a target=xrefwindow id=d28576e1884 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5712179">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d28576e1893 class=n-a></a>Peery AF, Crockett SD, Murphy CC, <i> et al.</i>: Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. <i>Gastroenterology.</i> 2019; <b>156</b>(1): 254–272.e11. <a target=xrefwindow id=d28576e1904 href="http://www.ncbi.nlm.nih.gov/pubmed/30315778">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1907 href="https://doi.org/10.1053/j.gastro.2018.08.063">Publisher Full Text </a> | <a target=xrefwindow id=d28576e1911 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6689327">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d28576e1920 class=n-a></a>Coward S, Clement F, Benchimol EI, <i> et al.</i>: Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. <i>Gastroenterology.</i> 2019; <b>156</b>(5): 1345–1353.e4. <a target=xrefwindow id=d28576e1931 href="http://www.ncbi.nlm.nih.gov/pubmed/30639677">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1934 href="https://doi.org/10.1053/j.gastro.2019.01.002">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732568747"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e1943 class=n-a></a>Singh S, George J, Boland BS, <i> et al.</i>: Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. <i>J Crohns Colitis.</i> 2018; <b>12</b>(6): 635–43. <a target=xrefwindow id=d28576e1954 href="http://www.ncbi.nlm.nih.gov/pubmed/29370397">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1957 href="https://doi.org/10.1093/ecco-jcc/jjy004">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732568747">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d28576e1970 class=n-a></a>Lee JC: Predicting the course of IBD: light at the end of the tunnel? <i>Dig Dis.</i> 2012; <b>30 Suppl 1</b>: 95–9. <a target=xrefwindow id=d28576e1978 href="http://www.ncbi.nlm.nih.gov/pubmed/23075876">PubMed Abstract </a> | <a target=xrefwindow id=d28576e1981 href="https://doi.org/10.1159/000341132">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d28576e1990 class=n-a></a>Lewis JD: The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. <i>Gastroenterology.</i> 2011; <b>140</b>(6): 1817–1826.e2. <a target=xrefwindow id=d28576e1998 href="http://www.ncbi.nlm.nih.gov/pubmed/21530748">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2001 href="https://doi.org/10.1053/j.gastro.2010.11.058">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2004 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3749298">Free Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734885577"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e2014 class=n-a></a>Olivera P, Danese S, Jay N, <i> et al.</i>: Big data in IBD: a look into the future. <i>Nat Rev Gastroenterol Hepatol.</i> 2019; <b>16</b>(5): 312–21. <a target=xrefwindow id=d28576e2025 href="http://www.ncbi.nlm.nih.gov/pubmed/30659247">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2028 href="https://doi.org/10.1038/s41575-019-0102-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734885577">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d28576e2041 class=n-a></a>Viennois E, Zhao Y, Merlin D: Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine. <i>Inflamm Bowel Dis.</i> 2015; <b>21</b>(10): 2467–74. <a target=xrefwindow id=d28576e2049 href="http://www.ncbi.nlm.nih.gov/pubmed/25985250">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2052 href="https://doi.org/10.1097/MIB.0000000000000444">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2055 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4567401">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734324470"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e2064 class=n-a></a>Stevens TW, Matheeuwsen M, Lönnkvist MH, <i> et al.</i>: Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. <i>Aliment Pharmacol Ther.</i> 2018; <b>48</b>(11–12): 1213–31. <a target=xrefwindow id=d28576e2075 href="http://www.ncbi.nlm.nih.gov/pubmed/30378142">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2078 href="https://doi.org/10.1111/apt.15033">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734324470">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d28576e2091 class=n-a></a>Orholm M, Fonager K, Sørensen HT: Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease. <i>Am J Gastroenterol.</i> 1999; <b>94</b>(11): 3236–8. <a target=xrefwindow id=d28576e2099 href="http://www.ncbi.nlm.nih.gov/pubmed/10566721">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2102 href="https://doi.org/10.1111/j.1572-0241.1999.01526.x">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d28576e2111 class=n-a></a>Spehlmann ME, Begun AZ, Burghardt J, <i> et al.</i>: Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. <i>Inflamm Bowel Dis.</i> 2008; <b>14</b>(7): 968–76. <a target=xrefwindow id=d28576e2122 href="http://www.ncbi.nlm.nih.gov/pubmed/18253950">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2125 href="https://doi.org/10.1002/ibd.20380">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d28576e2134 class=n-a></a>Moller FT, Andersen V, Wohlfahrt J, <i> et al.</i>: Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011. <i>Am J Gastroenterol.</i> 2015; <b>110</b>(4): 564–71. <a target=xrefwindow id=d28576e2145 href="http://www.ncbi.nlm.nih.gov/pubmed/25803400">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2148 href="https://doi.org/10.1038/ajg.2015.50">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d28576e2158 class=n-a></a>McGovern DP, Kugathasan S, Cho JH: Genetics of Inflammatory Bowel Diseases. <i>Gastroenterology.</i> 2015; <b>149</b>(5): 1163–1176.e2. <a target=xrefwindow id=d28576e2166 href="http://www.ncbi.nlm.nih.gov/pubmed/26255561">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2169 href="https://doi.org/10.1053/j.gastro.2015.08.001">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2172 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4915781">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d28576e2181 class=n-a></a>Ramos GP, Papadakis KA: Mechanisms of Disease: Inflammatory Bowel Diseases. <i>Mayo Clin Proc.</i> 2019; <b>94</b>(1): 155–65. <a target=xrefwindow id=d28576e2189 href="http://www.ncbi.nlm.nih.gov/pubmed/30611442">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2192 href="https://doi.org/10.1016/j.mayocp.2018.09.013">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2195 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6386158">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d28576e2204 class=n-a></a>Zhernakova A, van Diemen CC, Wijmenga C: Detecting shared pathogenesis from the shared genetics of immune-related diseases. <i>Nat Rev Genet.</i> 2009; <b>10</b>(1): 43–55. <a target=xrefwindow id=d28576e2212 href="http://www.ncbi.nlm.nih.gov/pubmed/19092835">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2215 href="https://doi.org/10.1038/nrg2489">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d28576e2224 class=n-a></a>Zhao M, Burisch J: Impact of Genes and the Environment on the Pathogenesis and Disease Course of Inflammatory Bowel Disease. <i>Dig Dis Sci.</i> 2019; <b>64</b>(7): 1759–69. <a target=xrefwindow id=d28576e2232 href="http://www.ncbi.nlm.nih.gov/pubmed/31073736">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2235 href="https://doi.org/10.1007/s10620-019-05648-w">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d28576e2244 class=n-a></a>Kaplan GG: The global burden of IBD: from 2015 to 2025. <i>Nat Rev Gastroenterol Hepatol.</i> 2015; <b>12</b>(12): 720–7. <a target=xrefwindow id=d28576e2252 href="http://www.ncbi.nlm.nih.gov/pubmed/26323879">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2255 href="https://doi.org/10.1038/nrgastro.2015.150">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d28576e2264 class=n-a></a>Rigottier-Gois L: Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis. <i>ISME J.</i> 2013; <b>7</b>(7): 1256–61. <a target=xrefwindow id=d28576e2272 href="http://www.ncbi.nlm.nih.gov/pubmed/23677008">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2275 href="https://doi.org/10.1038/ismej.2013.80">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2278 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3695303">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d28576e2288 class=n-a></a>Lloyd-Price J, Arze C, Ananthakrishnan AN, <i> et al.</i>: Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. <i>Nature.</i> 2019; <b>569</b>(7758): 655–62. <a target=xrefwindow id=d28576e2299 href="http://www.ncbi.nlm.nih.gov/pubmed/31142855">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2302 href="https://doi.org/10.1038/s41586-019-1237-9">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2306 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6650278">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d28576e2315 class=n-a></a>Park JH, Peyrin-Biroulet L, Eisenhut M, <i> et al.</i>: IBD immunopathogenesis: A comprehensive review of inflammatory molecules. <i>Autoimmun Rev.</i> 2017; <b>16</b>(4): 416–26. <a target=xrefwindow id=d28576e2326 href="http://www.ncbi.nlm.nih.gov/pubmed/28212924">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2329 href="https://doi.org/10.1016/j.autrev.2017.02.013">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d28576e2338 class=n-a></a>Rescigno M, Di Sabatino A: Dendritic cells in intestinal homeostasis and disease. <i>J Clin Invest.</i> 2009; <b>119</b>(9): 2441–50. <a target=xrefwindow id=d28576e2346 href="http://www.ncbi.nlm.nih.gov/pubmed/19729841">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2349 href="https://doi.org/10.1172/JCI39134">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2352 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2735931">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d28576e2361 class=n-a></a>Ahluwalia B, Moraes L, Magnusson MK, <i> et al.</i>: Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. <i>Scand J Gastroenterol.</i> 2018; <b>53</b>(4): 379–89. <a target=xrefwindow id=d28576e2372 href="http://www.ncbi.nlm.nih.gov/pubmed/29523023">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2375 href="https://doi.org/10.1080/00365521.2018.1447597">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d28576e2384 class=n-a></a>National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease: Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. The National Academies Collection: Reports funded by National Institutes of Health. Washington (DC): National Academies Press (US) National Academy of Sciences. 2011. <a target=xrefwindow id=d28576e2386 href="http://www.ncbi.nlm.nih.gov/pubmed/22536618">PubMed Abstract </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d28576e2395 class=n-a></a>Ginsburg GS, Phillips KA: Precision Medicine: From Science To Value. <i>Health Aff (Millwood).</i> 2018; <b>37</b>(5): 694–701. <a target=xrefwindow id=d28576e2403 href="http://www.ncbi.nlm.nih.gov/pubmed/29733705">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2406 href="https://doi.org/10.1377/hlthaff.2017.1624">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2409 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5989714">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725332633"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e2419 class=n-a></a>Collins FS, Varmus H: A new initiative on precision medicine. <i>N Engl J Med.</i> 2015; <b>372</b>(9): 793–5. <a target=xrefwindow id=d28576e2427 href="http://www.ncbi.nlm.nih.gov/pubmed/25635347">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2430 href="https://doi.org/10.1056/NEJMp1500523">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2433 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5101938">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725332633">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718140552"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e2446 class=n-a></a>Solberg IC, Lygren I, Jahnsen J, <i> et al.</i>: Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). <i>Scand J Gastroenterol.</i> 2009; <b>44</b>(4): 431–40. <a target=xrefwindow id=d28576e2457 href="http://www.ncbi.nlm.nih.gov/pubmed/19101844">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2460 href="https://doi.org/10.1080/00365520802600961">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718140552">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d28576e2473 class=n-a></a>Solberg IC, Vatn MH, Høie O, <i> et al.</i>: Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. <i>Clin Gastroenterol Hepatol.</i> 2007; <b>5</b>(12): 1430–8. <a target=xrefwindow id=d28576e2484 href="http://www.ncbi.nlm.nih.gov/pubmed/18054751">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2487 href="https://doi.org/10.1016/j.cgh.2007.09.002">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d28576e2496 class=n-a></a>Beaugerie L, Sokol H: Clinical, serological and genetic predictors of inflammatory bowel disease course. <i>World J Gastroenterol.</i> 2012; <b>18</b>(29): 3806–13. <a target=xrefwindow id=d28576e2504 href="http://www.ncbi.nlm.nih.gov/pubmed/22876031">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2507 href="https://doi.org/10.3748/wjg.v18.i29.3806">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2510 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3413051">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d28576e2519 class=n-a></a>Peyrin-Biroulet L, Panés J, Sandborn WJ, <i> et al.</i>: Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. <i>Clin Gastroenterol Hepatol.</i> 2016; <b>14</b>(3): 348–354.e17. <a target=xrefwindow id=d28576e2530 href="http://www.ncbi.nlm.nih.gov/pubmed/26071941">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2533 href="https://doi.org/10.1016/j.cgh.2015.06.001">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d28576e2542 class=n-a></a>de Lange KM, Moutsianas L, Lee JC, <i> et al.</i>: Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. <i>Nat Genet.</i> 2017; <b>49</b>(2): 256–61. <a target=xrefwindow id=d28576e2553 href="http://www.ncbi.nlm.nih.gov/pubmed/28067908">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2556 href="https://doi.org/10.1038/ng.3760">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2560 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5289481">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732911416"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e2570 class=n-a></a>Hong M, Ye BD, Yang SK, <i> et al.</i>: Immunochip Meta-Analysis of Inflammatory Bowel Disease Identifies Three Novel Loci and Four Novel Associations in Previously Reported Loci. <i>J Crohns Colitis.</i> 2018; <b>12</b>(6): 730–41. <a target=xrefwindow id=d28576e2581 href="http://www.ncbi.nlm.nih.gov/pubmed/29584801">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2584 href="https://doi.org/10.1093/ecco-jcc/jjy002">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2588 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6279085">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732911416">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725658435"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e2601 class=n-a></a>Liu JZ, van Sommeren S, Huang H, <i> et al.</i>: Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. <i>Nat Genet.</i> 2015; <b>47</b>(9): 979–86. <a target=xrefwindow id=d28576e2612 href="http://www.ncbi.nlm.nih.gov/pubmed/26192919">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2615 href="https://doi.org/10.1038/ng.3359">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2619 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4881818">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725658435">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717961892"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e2632 class=n-a></a>Jostins L, Ripke S, Weersma RK, <i> et al.</i>: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. <i>Nature.</i> 2012; <b>491</b>(7422): 119–24. <a target=xrefwindow id=d28576e2643 href="http://www.ncbi.nlm.nih.gov/pubmed/23128233">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2646 href="https://doi.org/10.1038/nature11582">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2650 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3491803">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717961892">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d28576e2663 class=n-a></a>Girardin SE, Hugot JP, Sansonetti PJ: Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. <i>Trends Immunol.</i> 2003; <b>24</b>(12): 652–8. <a target=xrefwindow id=d28576e2671 href="http://www.ncbi.nlm.nih.gov/pubmed/14644139">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2674 href="https://doi.org/10.1016/j.it.2003.10.007">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d28576e2683 class=n-a></a>Abreu MT, Taylor KD, Lin YC, <i> et al.</i>: Mutations in <i>NOD2</i> are associated with fibrostenosing disease in patients with Crohn's disease. <i>Gastroenterology.</i> 2002; <b>123</b>(3): 679–88. <a target=xrefwindow id=d28576e2697 href="http://www.ncbi.nlm.nih.gov/pubmed/12198692">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2701 href="https://doi.org/10.1053/gast.2002.35393">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d28576e2710 class=n-a></a>Lesage S, Zouali H, Cézard JP, <i> et al.</i>: <i>CARD15/NOD2</i> mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. <i>Am J Hum Genet.</i> 2002; <b>70</b>(4): 845–57. <a target=xrefwindow id=d28576e2724 href="http://www.ncbi.nlm.nih.gov/pubmed/11875755">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2728 href="https://doi.org/10.1086/339432">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2731 href="http://www.ncbi.nlm.nih.gov/pmc/articles/379113">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d28576e2741 class=n-a></a>Cuthbert AP, Fisher SA, Mirza MM, <i> et al.</i>: The contribution of <i>NOD2</i> gene mutations to the risk and site of disease in inflammatory bowel disease. <i>Gastroenterology.</i> 2002; <b>122</b>(4): 867–74. <a target=xrefwindow id=d28576e2755 href="http://www.ncbi.nlm.nih.gov/pubmed/11910337">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2759 href="https://doi.org/10.1053/gast.2002.32415">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d28576e2768 class=n-a></a>Cleynen I, González JR, Figueroa C, <i> et al.</i>: Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. <i>Gut.</i> 2013; <b>62</b>(11): 1556–65. <a target=xrefwindow id=d28576e2779 href="http://www.ncbi.nlm.nih.gov/pubmed/23263249">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2782 href="https://doi.org/10.1136/gutjnl-2011-300777">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d28576e2791 class=n-a></a>Salem M, Ammitzboell M, Nys K, <i> et al.</i>: ATG16L1: A multifunctional susceptibility factor in Crohn disease. <i>Autophagy.</i> 2015; <b>11</b>(4): 585–94. <a target=xrefwindow id=d28576e2802 href="http://www.ncbi.nlm.nih.gov/pubmed/25906181">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2805 href="https://doi.org/10.1080/15548627.2015.1017187">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2809 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4502774">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d28576e2818 class=n-a></a>Fowler EV, Doecke J, Simms LA, <i> et al.</i>: ATG16L1 T300A shows strong associations with disease subgroups in a large Australian IBD population: further support for significant disease heterogeneity. <i>Am J Gastroenterol.</i> 2008; <b>103</b>(10): 2519–26. <a target=xrefwindow id=d28576e2829 href="http://www.ncbi.nlm.nih.gov/pubmed/18671817">PubMed Abstract </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d28576e2838 class=n-a></a>Latiano A, Palmieri O, Cucchiara S, <i> et al.</i>: Polymorphism of the IRGM gene might predispose to fistulizing behavior in Crohn's disease. <i>Am J Gastroenterol.</i> 2009; <b>104</b>(1): 110–6. <a target=xrefwindow id=d28576e2849 href="http://www.ncbi.nlm.nih.gov/pubmed/19098858">PubMed Abstract </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d28576e2858 class=n-a></a>Deepak P, Sandborn WJ: Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. <i>Gastroenterol Clin North Am.</i> 2017; <b>46</b>(3): 603–26. <a target=xrefwindow id=d28576e2866 href="http://www.ncbi.nlm.nih.gov/pubmed/28838418">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2869 href="https://doi.org/10.1016/j.gtc.2017.05.013">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1047044"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e2879 class=n-a></a>Duerr RH, Taylor KD, Brant SR, <i> et al.</i>: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. <i>Science.</i> 2006; <b>314</b>(5804): 1461–3. <a target=xrefwindow id=d28576e2890 href="http://www.ncbi.nlm.nih.gov/pubmed/17068223">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2893 href="https://doi.org/10.1126/science.1135245">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2897 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4410764">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1047044">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d28576e2910 class=n-a></a>Okazaki T, Wang MH, Rawsthorne P, <i> et al.</i>: Contributions of <i>IBD5</i>, <i>IL23R</i>, <i>ATG16L1</i>, and <i>NOD2</i> to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions. <i>Inflamm Bowel Dis.</i> 2008; <b>14</b>(11): 1528–41. <a target=xrefwindow id=d28576e2934 href="http://www.ncbi.nlm.nih.gov/pubmed/18521914">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2937 href="https://doi.org/10.1002/ibd.20512">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2940 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3336049">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725869432"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e2949 class=n-a></a>Cleynen I, Boucher G, Jostins L, <i> et al.</i>: Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. <i>Lancet.</i> 2016; <b>387</b>(10014): 156–67. <a target=xrefwindow id=d28576e2960 href="http://www.ncbi.nlm.nih.gov/pubmed/26490195">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2963 href="https://doi.org/10.1016/S0140-6736(15)00465-1">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2967 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4714968">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725869432">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718312064"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e2980 class=n-a></a>Gevers D, Kugathasan S, Denson LA, <i> et al.</i>: The treatment-naive microbiome in new-onset Crohn's disease. <i>Cell Host Microbe.</i> 2014; <b>15</b>(3): 382–92. <a target=xrefwindow id=d28576e2991 href="http://www.ncbi.nlm.nih.gov/pubmed/24629344">PubMed Abstract </a> | <a target=xrefwindow id=d28576e2994 href="https://doi.org/10.1016/j.chom.2014.02.005">Publisher Full Text </a> | <a target=xrefwindow id=d28576e2998 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4059512">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718312064">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727289090"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e3011 class=n-a></a>Pascal V, Pozuelo M, Borruel N, <i> et al.</i>: A microbial signature for Crohn's disease. <i>Gut.</i> 2017; <b>66</b>(5): 813–22. <a target=xrefwindow id=d28576e3022 href="http://www.ncbi.nlm.nih.gov/pubmed/28179361">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3025 href="https://doi.org/10.1136/gutjnl-2016-313235">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3029 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5531220">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727289090">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d28576e3042 class=n-a></a>Papa E, Docktor M, Smillie C, <i> et al.</i>: Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. <i>PLoS One.</i> 2012; <b>7</b>(6): e39242. <a target=xrefwindow id=d28576e3053 href="http://www.ncbi.nlm.nih.gov/pubmed/22768065">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3056 href="https://doi.org/10.1371/journal.pone.0039242">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3060 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3387146">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d28576e3070 class=n-a></a>Somineni HK, Kugathasan S: The Microbiome in Patients With Inflammatory Diseases. <i>Clin Gastroenterol Hepatol.</i> 2019; <b>17</b>(2): 243–55. <a target=xrefwindow id=d28576e3078 href="http://www.ncbi.nlm.nih.gov/pubmed/30196163">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3081 href="https://doi.org/10.1016/j.cgh.2018.08.078">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d28576e3090 class=n-a></a>van Rheenen PF, Van de Vijver E, Fidler V: Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. <i>BMJ.</i> 2010; <b>341</b>: c3369. <a target=xrefwindow id=d28576e3098 href="http://www.ncbi.nlm.nih.gov/pubmed/20634346">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3101 href="https://doi.org/10.1136/bmj.c3369">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3104 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2904879">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d28576e3113 class=n-a></a>Kennedy NA, Clark A, Walkden A, <i> et al.</i>: Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16–50 years. <i>J Crohns Colitis.</i> 2015; <b>9</b>(1): 41–9. <a target=xrefwindow id=d28576e3124 href="http://www.ncbi.nlm.nih.gov/pubmed/25135754">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3127 href="https://doi.org/10.1016/j.crohns.2014.07.005">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3131 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4795527">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d28576e3140 class=n-a></a>NICE: DG11: Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. London: NICE; 2013. <a target=xrefwindow id=d28576e3142 href="https://www.nice.org.uk/guidance/dg11">Reference Source</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d28576e3151 class=n-a></a>Maréchal C, Aimone-Gastin I, Baumann C, <i> et al.</i>: Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. <i>United European Gastroenterol J.</i> 2017; <b>5</b>(5): 702–7. <a target=xrefwindow id=d28576e3162 href="http://www.ncbi.nlm.nih.gov/pubmed/28815034">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3165 href="https://doi.org/10.1177/2050640616686517">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3169 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5548356">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d28576e3178 class=n-a></a>Kalla R, Boyapati R, Vatn S, <i> et al.</i>: Patients’ perceptions of faecal calprotectin testing in inflammatory bowel disease: Results from a prospective multicentre patient-based survey. <i>Scand J Gastroenterol.</i> 2018; <b>53</b>(12): 1437–42. <a target=xrefwindow id=d28576e3189 href="http://www.ncbi.nlm.nih.gov/pubmed/30451040">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3192 href="https://doi.org/10.1080/00365521.2018.1527394">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727679246"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e3202 class=n-a></a>Buisson A, Gonzalez F, Poullenot F, <i> et al.</i>: Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. <i>Inflamm Bowel Dis.</i> 2017; <b>23</b>(8): 1425–33. <a target=xrefwindow id=d28576e3213 href="http://www.ncbi.nlm.nih.gov/pubmed/28570431">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3216 href="https://doi.org/10.1097/MIB.0000000000001140">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727679246">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d28576e3229 class=n-a></a>Calafat M, Cabré E, Mañosa M, <i> et al.</i>: High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? <i>Inflamm Bowel Dis.</i> 2015; <b>21</b>(5): 1072–6. <a target=xrefwindow id=d28576e3240 href="http://www.ncbi.nlm.nih.gov/pubmed/25793326">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3243 href="https://doi.org/10.1097/MIB.0000000000000349">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d28576e3252 class=n-a></a>Du L, Foshaug R, Huang VW, <i> et al.</i>: Within-Stool and Within-Day Sample Variability of Fecal Calprotectin in Patients With Inflammatory Bowel Disease: A Prospective Observational Study. <i>J Clin Gastroenterol.</i> 2018; <b>52</b>(3): 235–40. <a target=xrefwindow id=d28576e3263 href="http://www.ncbi.nlm.nih.gov/pubmed/28009684 ">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3266 href="https://doi.org/10.1097/MCG.0000000000000776">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d28576e3275 class=n-a></a>Satsangi J, Kitten O, Chavez M, <i> et al.</i>: How to Apply for and Secure EU Funding for Collaborative IBD Research Projects. <i>J Crohns Colitis.</i> 2016; <b>10</b>(3): 363–70. <a target=xrefwindow id=d28576e3286 href="http://www.ncbi.nlm.nih.gov/pubmed/26744440">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3289 href="https://doi.org/10.1093/ecco-jcc/jjv237">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3293 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4957481">Free Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d28576e3302 class=n-a></a>Vermeire S, Van Assche G, Rutgeerts P: Laboratory markers in IBD: useful, magic, or unnecessary toys? <i>Gut.</i> 2006; <b>55</b>(3): 426–31. <a target=xrefwindow id=d28576e3310 href="http://www.ncbi.nlm.nih.gov/pubmed/16474109">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3313 href="https://doi.org/10.1136/gut.2005.069476">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3316 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1856093 ">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d28576e3325 class=n-a></a>Ho GT, Lee HM, Brydon G, <i> et al.</i>: Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. <i>Am J Gastroenterol.</i> 2009; <b>104</b>(3): 673–8. <a target=xrefwindow id=d28576e3336 href="http://www.ncbi.nlm.nih.gov/pubmed/19262524">PubMed Abstract </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d28576e3346 class=n-a></a>Kennedy NA, Jones GR, Plevris N, <i> et al.</i>: Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease. <i>Clin Gastroenterol Hepatol.</i> 2019; <b>17</b>(11): 2269–2276.e4. <a target=xrefwindow id=d28576e3357 href="http://www.ncbi.nlm.nih.gov/pubmed/30772585">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3360 href="https://doi.org/10.1016/j.cgh.2019.02.017">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3364 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6880783">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d28576e3373 class=n-a></a>Kalla R, Kennedy NA, Ventham NT, <i> et al.</i>: Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases. <i>Am J Gastroenterol.</i> 2016; <b>111</b>(12): 1796–805. <a target=xrefwindow id=d28576e3384 href="http://www.ncbi.nlm.nih.gov/pubmed/27596694">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3387 href="https://doi.org/10.1038/ajg.2016.342">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717979505"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e3396 class=n-a></a>Lee JC, Lyons PA, McKinney EF, <i> et al.</i>: Gene expression profiling of CD8<sup>+</sup> T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. <i>J Clin Invest.</i> 2011; <b>121</b>(10): 4170–9. <a target=xrefwindow id=d28576e3410 href="http://www.ncbi.nlm.nih.gov/pubmed/21946256">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3414 href="https://doi.org/10.1172/JCI59255">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3417 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3196314">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717979505">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735622905"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e3430 class=n-a></a>Biasci D, Lee JC, Noor NM, <i> et al.</i>: A blood-based prognostic biomarker in IBD. <i>Gut.</i> 2019; <b>68</b>(8): 1386–95. <a target=xrefwindow id=d28576e3441 href="http://www.ncbi.nlm.nih.gov/pubmed/31030191">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3444 href="https://doi.org/10.1136/gutjnl-2019-318343">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3448 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6691955">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735622905">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d28576e3461 class=n-a></a>Lee JC, Biasci D, Roberts R, <i> et al.</i>: Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease. <i>Nat Genet.</i> 2017; <b>49</b>(2): 262–8. <a target=xrefwindow id=d28576e3472 href="http://www.ncbi.nlm.nih.gov/pubmed/28067912">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3475 href="https://doi.org/10.1038/ng.3755">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3479 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5730041">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d28576e3488 class=n-a></a>Kalla R, Adams A, Vatn S, <i> et al.</i>: Proximity Extension Assay based Proteins Show Immune Cell Specificity and can Diagnose and Predict Outcomes in Inflammatory Bowel Diseases: IBD Character Study. <i>Gastroenterology.</i> 2017; <b>152</b>: S606–S607. <a target=xrefwindow id=d28576e3499 href="https://doi.org/10.1016/S0016-5085(17)32161-3">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d28576e3509 class=n-a></a>Kalla R, Adams A, Vatn S, <i> et al.</i>: OC-047 Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – ibd character. <i>Gut.</i> 2017; <b>66</b>(Suppl 2): A24–A5. <a target=xrefwindow id=d28576e3520 href="https://doi.org/10.1136/gutjnl-2017-314472.47">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d28576e3529 class=n-a></a>Ventham NT, Kennedy NA, Adams AT, <i> et al.</i>: Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease. <i>Nat Commun.</i> 2016; <b>7</b>: 13507. <a target=xrefwindow id=d28576e3540 href="http://www.ncbi.nlm.nih.gov/pubmed/27886173">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3543 href="https://doi.org/10.1038/ncomms13507">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3547 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5133631">Free Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d28576e3556 class=n-a></a>Trbojević Akmačić I, Ventham NT, Theodoratou E, <i> et al.</i>: Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome. <i>Inflamm Bowel Dis.</i> 2015; <b>21</b>(6): 1237–47. <a target=xrefwindow id=d28576e3567 href="http://www.ncbi.nlm.nih.gov/pubmed/25895110">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3570 href="https://doi.org/10.1097/MIB.0000000000000372">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3574 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4450892">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d28576e3583 class=n-a></a>Shubhakar A, Jansen B, Adams A, <i> et al.</i>: DOP10 Serum N-glycomic biomarkers predict treatment escalation in inflammatory bowel disease. <i>J Crohns Colitis.</i> 2019; <b>13</b>: S032–S033. <a target=xrefwindow id=d28576e3594 href="https://doi.org/10.1093/ecco-jcc/jjy222.045">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d28576e3603 class=n-a></a>Beaugerie L, Seksik P, Nion-Larmurier I, <i> et al.</i>: Predictors of Crohn's disease. <i>Gastroenterology.</i> 2006; <b>130</b>(3): 650–6. <a target=xrefwindow id=d28576e3614 href="http://www.ncbi.nlm.nih.gov/pubmed/16530505">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3617 href="https://doi.org/10.1053/j.gastro.2005.12.019">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d28576e3626 class=n-a></a>Loly C, Belaiche J, Louis E: Predictors of severe Crohn's disease. <i>Scand J Gastroenterol.</i> 2009; <b>43</b>(8): 948–54. <a target=xrefwindow id=d28576e3634 href="http://www.ncbi.nlm.nih.gov/pubmed/19086165">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3637 href="https://doi.org/10.1080/00365520801957149">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d28576e3647 class=n-a></a>Henriksen M, Jahnsen J, Lygren I, <i> et al.</i>: Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study. <i>Am J Gastroenterol.</i> 2007; <b>102</b>(9): 1955–63. <a target=xrefwindow id=d28576e3658 href="http://www.ncbi.nlm.nih.gov/pubmed/17573793">PubMed Abstract </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d28576e3667 class=n-a></a>Clerc F, Novokmet M, Dotz V, <i> et al.</i>: Plasma <i>N</i>-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases. <i>Gastroenterology.</i> 2018; <b>155</b>(3): 829–43. <a target=xrefwindow id=d28576e3681 href="http://www.ncbi.nlm.nih.gov/pubmed/29792883">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3685 href="https://doi.org/10.1053/j.gastro.2018.05.030">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d28576e3694 class=n-a></a>Wolters FL, Russel MG, Sijbrandij J, <i> et al.</i>: Phenotype at diagnosis predicts recurrence rates in Crohn's disease. <i>Gut.</i> 2005; <b>55</b>(8): 1124–30. <a target=xrefwindow id=d28576e3705 href="http://www.ncbi.nlm.nih.gov/pubmed/16361306 ">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3708 href="https://doi.org/10.1136/gut.2005.084061">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3712 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1856253">Free Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d28576e3721 class=n-a></a>Höie O, Wolters F, Riis L, <i> et al.</i>: Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. <i>Am J Gastroenterol.</i> 2007; <b>102</b>(8): 1692–701. <a target=xrefwindow id=d28576e3732 href="http://www.ncbi.nlm.nih.gov/pubmed/17555460">PubMed Abstract </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d28576e3741 class=n-a></a>Langholz E, Munkholm P, Davidsen M, <i> et al.</i>: Course of ulcerative colitis: analysis of changes in disease activity over years. <i>Gastroenterology.</i> 1994; <b>107</b>(1): 3–11. <a target=xrefwindow id=d28576e3752 href="http://www.ncbi.nlm.nih.gov/pubmed/8020674">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3755 href="https://doi.org/10.1016/0016-5085(94)90054-x">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d28576e3764 class=n-a></a>Hoie O, Wolters FL, Riis L, <i> et al.</i>: Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. <i>Gastroenterology.</i> 2007; <b>132</b>(2): 507–5. <a target=xrefwindow id=d28576e3775 href="http://www.ncbi.nlm.nih.gov/pubmed/17258717">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3778 href="https://doi.org/10.1053/j.gastro.2006.11.015">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727372624"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e3788 class=n-a></a>Kugathasan S, Denson LA, Walters TD, <i> et al.</i>: Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. <i>Lancet.</i> 2017; <b>389</b>: 1710–8. <a target=xrefwindow id=d28576e3799 href="http://www.ncbi.nlm.nih.gov/pubmed/28259484">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3802 href="https://doi.org/10.1016/S0140-6736(17)30317-3">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3806 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5719489">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727372624">F1000 Recommendation</a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d28576e3819 class=n-a></a>Marigorta UM, Denson LA, Hyams JS, <i> et al.</i>: Transcriptional risk scores link GWAS to eQTLs and predict complications in Crohn's disease. <i>Nat Genet.</i> 2017; <b>49</b>(10): 1517–21. <a target=xrefwindow id=d28576e3830 href="http://www.ncbi.nlm.nih.gov/pubmed/28805827">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3833 href="https://doi.org/10.1038/ng.3936">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3837 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5745037">Free Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1135879"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e3846 class=n-a></a>Sokol H, Pigneur B, Watterlot L, <i> et al.</i>: <i>Faecalibacterium prausnitzii</i> is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. <i>Proc Natl Acad Sci U S A.</i> 2008; <b>105</b>(43): 16731–6. <a target=xrefwindow id=d28576e3860 href="http://www.ncbi.nlm.nih.gov/pubmed/18936492">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3864 href="https://doi.org/10.1073/pnas.0804812105">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3867 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2575488 ">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1135879">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718484213"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e3880 class=n-a></a>Haberman Y, Tickle TL, Dexheimer PJ, <i> et al.</i>: Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. <i>J Clin Invest.</i> 2014; <b>124</b>(8): 3617–33. <a target=xrefwindow id=d28576e3891 href="http://www.ncbi.nlm.nih.gov/pubmed/25003194">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3894 href="https://doi.org/10.1172/JCI75436">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3898 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4109533">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718484213">F1000 Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732071152"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e3911 class=n-a></a>Colombel JF, Panaccione R, Bossuyt P, <i> et al.</i>: Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. <i>Lancet.</i> 2018; <b>390</b>(10114): 2779–89. <a target=xrefwindow id=d28576e3922 href="http://www.ncbi.nlm.nih.gov/pubmed/29096949">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3925 href="https://doi.org/10.1016/S0140-6736(17)32641-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732071152">F1000 Recommendation</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d28576e3938 class=n-a></a>Dean L: Azathioprine Therapy and <i>TPMT</i> Genotype. In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. <i>Medical Genetics Summaries.</i> Bethesda (MD): National Center for Biotechnology Information (US). 2012. <a target=xrefwindow id=d28576e3946 href="http://www.ncbi.nlm.nih.gov/pubmed/28520349">PubMed Abstract </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d28576e3956 class=n-a></a>Yang SK, Hong M, Baek J, <i> et al.</i>: A common missense variant in <i>NUDT15</i> confers susceptibility to thiopurine-induced leukopenia. <i>Nat Genet.</i> 2014; <b>46</b>(9): 1017–20. <a target=xrefwindow id=d28576e3970 href="http://www.ncbi.nlm.nih.gov/pubmed/25108385">PubMed Abstract </a> | <a target=xrefwindow id=d28576e3974 href="https://doi.org/10.1038/ng.3060">Publisher Full Text </a> | <a target=xrefwindow id=d28576e3977 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4999337">Free Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d28576e3986 class=n-a></a>Moriyama T, Nishii R, Perez-Andreu V, <i> et al.</i>: <i>NUDT15</i> polymorphisms alter thiopurine metabolism and hematopoietic toxicity. <i>Nat Genet.</i> 2016; <b>48</b>(4): 367–73. <a target=xrefwindow id=d28576e4000 href="http://www.ncbi.nlm.nih.gov/pubmed/26878724">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4004 href="https://doi.org/10.1038/ng.3508">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4007 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5029084">Free Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d28576e4016 class=n-a></a>Walker GJ, Harrison JW, Heap GA, <i> et al.</i>: Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA.</i> 2019; <b>321</b>(8): 773–785. <a target=xrefwindow id=d28576e4030 href="http://www.ncbi.nlm.nih.gov/pubmed/30806694">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4034 href="https://doi.org/10.1001/jama.2019.0709">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4037 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6439872">Free Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d28576e4046 class=n-a></a>Heap GA, Weedon MN, Bewshea CM, <i> et al.</i>: <i>HLA-DQA1-HLA-DRB1</i> variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nat Genet.</i> 2014; <b>46</b>(10): 1131–4. <a target=xrefwindow id=d28576e4060 href="http://www.ncbi.nlm.nih.gov/pubmed/25217962">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4064 href="https://doi.org/10.1038/ng.3093">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4067 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6379053">Free Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d28576e4076 class=n-a></a>Warner B, Johnston E, Arenas-Hernandez M, <i> et al.</i>: A practical guide to thiopurine prescribing and monitoring in IBD. <i>Frontline Gastroenterol.</i> 2018; <b>9</b>(1): 10–5. <a target=xrefwindow id=d28576e4087 href="http://www.ncbi.nlm.nih.gov/pubmed/29484155">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4090 href="https://doi.org/10.1136/flgastro-2016-100738">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4094 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5824765">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d28576e4103 class=n-a></a>de Boer NKH, Peyrin-Biroulet L, Jharap B, <i> et al.</i>: Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. <i>J Crohns Colitis.</i> 2018; <b>12</b>(5): 610–20. <a target=xrefwindow id=d28576e4114 href="http://www.ncbi.nlm.nih.gov/pubmed/29293971">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4117 href="https://doi.org/10.1093/ecco-jcc/jjx181">Publisher Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d28576e4127 class=n-a></a>Mitrev N, Vande Casteele N, Seow CH, <i> et al.</i>: Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. <i>Aliment Pharmacol Ther.</i> 2017; <b>46</b>(11–12): 1037–53. <a target=xrefwindow id=d28576e4138 href="http://www.ncbi.nlm.nih.gov/pubmed/29027257">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4141 href="https://doi.org/10.1111/apt.14368">Publisher Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718045301"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4150 class=n-a></a>Steenholdt C, Brynskov J, Thomsen OØ, <i> et al.</i>: Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. <i>Gut.</i> 2014; <b>63</b>(6): 919–27. <a target=xrefwindow id=d28576e4161 href="http://www.ncbi.nlm.nih.gov/pubmed/23878167">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4164 href="https://doi.org/10.1136/gutjnl-2013-305279">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718045301">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d28576e4177 class=n-a></a>Vande Casteele N, Ferrante M, Van Assche G, <i> et al.</i>: Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. <i>Gastroenterology.</i> 2015; <b>148</b>(7): 1320–1329.e3. <a target=xrefwindow id=d28576e4188 href="http://www.ncbi.nlm.nih.gov/pubmed/25724455">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4191 href="https://doi.org/10.1053/j.gastro.2015.02.031">Publisher Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732442410"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4200 class=n-a></a>D’Haens G, Vermeire S, Lambrecht G, <i> et al.</i>: Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease. <i>Gastroenterology.</i> 2018; <b>154</b>(5): 1343–1351.e1. <a target=xrefwindow id=d28576e4211 href="http://www.ncbi.nlm.nih.gov/pubmed/29317275">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4214 href="https://doi.org/10.1053/j.gastro.2018.01.004">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732442410">F1000 Recommendation</a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733815374"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4227 class=n-a></a>Ricciuto A, Dhaliwal J, Walters TD, <i> et al.</i>: Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis. <i>J Crohns Colitis.</i> 2018; <b>12</b>(11): 1302–15. <a target=xrefwindow id=d28576e4238 href="http://www.ncbi.nlm.nih.gov/pubmed/30107416">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4241 href="https://doi.org/10.1093/ecco-jcc/jjy109">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733815374">F1000 Recommendation</a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727471255"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4254 class=n-a></a>West NR, Hegazy AN, Owens BMJ, <i> et al.</i>: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. <i>Nat Med.</i> 2017; <b>23</b>(5): 579–89. <a target=xrefwindow id=d28576e4265 href="http://www.ncbi.nlm.nih.gov/pubmed/28368383">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4268 href="https://doi.org/10.1038/nm.4307">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4272 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5420447">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727471255">F1000 Recommendation</a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734931832"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4286 class=n-a></a>Verstockt B, Verstockt S, Dehairs J, <i> et al.</i>: Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. <i>EBioMedicine.</i> 2019; <b>40</b>: 733–42. <a target=xrefwindow id=d28576e4297 href="http://www.ncbi.nlm.nih.gov/pubmed/30685385">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4300 href="https://doi.org/10.1016/j.ebiom.2019.01.027">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4304 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6413341">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734931832">F1000 Recommendation</a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733593257"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4317 class=n-a></a>Telesco SE, Brodmerkel C, Zhang H, <i> et al.</i>: Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. <i>Gastroenterology.</i> 2018; <b>155</b>(4): 1008–1011.e8. <a target=xrefwindow id=d28576e4328 href="http://www.ncbi.nlm.nih.gov/pubmed/29981298">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4331 href="https://doi.org/10.1053/j.gastro.2018.06.077">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733593257">F1000 Recommendation</a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734028145"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4344 class=n-a></a>Morilla I, Uzzan M, Laharie D, <i> et al.</i>: Colonic MicroRNA Profiles, Identified by a Deep Learning Algorithm, That Predict Responses to Therapy of Patients With Acute Severe Ulcerative Colitis. <i>Clin Gastroenterol Hepatol.</i> 2019; <b>17</b>(5): 905–13. <a target=xrefwindow id=d28576e4355 href="http://www.ncbi.nlm.nih.gov/pubmed/30223112">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4358 href="https://doi.org/10.1016/j.cgh.2018.08.068">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734028145">F1000 Recommendation</a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d28576e4371 class=n-a></a>Kolho KL, Korpela K, Jaakkola T, <i> et al.</i>: Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation. <i>Am J Gastroenterol.</i> 2015; <b>110</b>(6): 921–30. <a target=xrefwindow id=d28576e4382 href="http://www.ncbi.nlm.nih.gov/pubmed/25986361">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4385 href="https://doi.org/10.1038/ajg.2015.149">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727604769"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4394 class=n-a></a>Ananthakrishnan AN, Luo C, Yajnik V, <i> et al.</i>: Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. <i>Cell Host Microbe.</i> 2017; <b>21</b>(5): 603–610.e3. <a target=xrefwindow id=d28576e4405 href="http://www.ncbi.nlm.nih.gov/pubmed/28494241">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4408 href="https://doi.org/10.1016/j.chom.2017.04.010">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4412 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5705050">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727604769">F1000 Recommendation</a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732845043"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4425 class=n-a></a>Doherty MK, Ding T, Koumpouras C, <i> et al.</i>: Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients. <i>mBio.</i> 2018; <b>9</b>(2): pii: e02120-17. <a target=xrefwindow id=d28576e4436 href="http://www.ncbi.nlm.nih.gov/pubmed/29535202">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4439 href="https://doi.org/10.1128/mBio.02120-17">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4443 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5850325">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732845043">F1000 Recommendation</a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d28576e4457 class=n-a></a>Kennedy NA, Heap GA, Green HD, <i> et al.</i>: Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. <i>Lancet Gastroenterol Hepatol.</i> 2019; <b>4</b>(5): 341–53. <a target=xrefwindow id=d28576e4468 href="http://www.ncbi.nlm.nih.gov/pubmed/30824404">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4471 href="https://doi.org/10.1016/S2468-1253(19)30012-3">Publisher Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d28576e4480 class=n-a></a>Sazonovs A, Kennedy NA, Bewshea C, <i> et al.</i>: OP013 HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s disease. <i>J Crohns Colitis.</i> 2018; <b>12</b>(supplement_1): S009–S010. <a target=xrefwindow id=d28576e4491 href="https://doi.org/10.1093/ecco-jcc/jjx180.012">Publisher Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734056014"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4500 class=n-a></a>Pereira MS, Maia L, Azevedo LF, <i> et al.</i>: A [Glyco]biomarker that Predicts Failure to Standard Therapy in Ulcerative Colitis Patients. <i>J Crohns Colitis.</i> 2019; <b>13</b>(1): 39–49. <a target=xrefwindow id=d28576e4511 href="http://www.ncbi.nlm.nih.gov/pubmed/30239648">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4514 href="https://doi.org/10.1093/ecco-jcc/jjy139">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734056014">F1000 Recommendation</a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734756037"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4527 class=n-a></a>Haberman Y, Karns R, Dexheimer PJ, <i> et al.</i>: Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. <i>Nat Commun.</i> 2019; <b>10</b>(1): 38. <a target=xrefwindow id=d28576e4538 href="http://www.ncbi.nlm.nih.gov/pubmed/30604764">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4541 href="https://doi.org/10.1038/s41467-018-07841-3">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4545 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6318335">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734756037">F1000 Recommendation</a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d28576e4558 class=n-a></a>Cunningham KE, Vincent G, Sodhi CP, <i> et al.</i>: Peroxisome Proliferator-activated Receptor-γ Coactivator 1-α (PGC1α) Protects against Experimental Murine Colitis. <i>J Biol Chem.</i> 2016; <b>291</b>(19): 10184–200. <a target=xrefwindow id=d28576e4569 href="http://www.ncbi.nlm.nih.gov/pubmed/26969166">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4572 href="https://doi.org/10.1074/jbc.M115.688812">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4576 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4858969">Free Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d28576e4585 class=n-a></a>Martin JC, Chang C, Boschetti G, <i> et al.</i>: Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. <i>Cell.</i> 2019; <b>178</b>(6): 1493–1508.e20. <a target=xrefwindow id=d28576e4596 href="http://www.ncbi.nlm.nih.gov/pubmed/31474370">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4599 href="https://doi.org/10.1016/j.cell.2019.08.008">Publisher Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732925501"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4609 class=n-a></a>Ma C, Hussein IM, Al-Abbar YJ, <i> et al.</i>: Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review. <i>Clin Gastroenterol Hepatol.</i> 2018; <b>16</b>(9): 1407–1419.e22. <a target=xrefwindow id=d28576e4620 href="http://www.ncbi.nlm.nih.gov/pubmed/29596987">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4623 href="https://doi.org/10.1016/j.cgh.2018.02.051">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732925501">F1000 Recommendation</a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/729280962"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4636 class=n-a></a>Ma C, Panaccione R, Fedorak RN, <i> et al.</i>: Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clin Gastroenterol Hepatol.</i> 2018; <b>16</b>(5): 637–647.e13. <a target=xrefwindow id=d28576e4647 href="http://www.ncbi.nlm.nih.gov/pubmed/28843356">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4650 href="https://doi.org/10.1016/j.cgh.2017.08.025">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/729280962">F1000 Recommendation</a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d28576e4663 class=n-a></a>Peyrin-Biroulet L, Sandborn W, Sands BE, <i> et al.</i>: Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. <i>Am J Gastroenterol.</i> 2015; <b>110</b>(9): 1324–38. <a target=xrefwindow id=d28576e4674 href="http://www.ncbi.nlm.nih.gov/pubmed/26303131">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4677 href="https://doi.org/10.1038/ajg.2015.233">Publisher Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d28576e4686 class=n-a></a>Yzet C, Ungaro R, Bossuyt P, <i> et al.</i>: OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: Long-term data from CALM. <i>J Crohns Colitis.</i> 2019; <b>13</b>: S024–S025. <a target=xrefwindow id=d28576e4697 href="https://doi.org/10.1093/ecco-jcc/jjy222.032">Publisher Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727629398"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4706 class=n-a></a>Heida A, Park KT, van Rheenen PF: Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. <i>Inflamm Bowel Dis.</i> 2017; <b>23</b>(6): 894–902. <a target=xrefwindow id=d28576e4714 href="http://www.ncbi.nlm.nih.gov/pubmed/28511198">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4717 href="https://doi.org/10.1097/MIB.0000000000001082">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4720 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5434712">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727629398">F1000 Recommendation</a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d28576e4733 class=n-a></a>DʼHaens G, Ferrante M, Vermeire S, <i> et al.</i>: Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. <i>Inflamm Bowel Dis.</i> 2012; <b>18</b>(12): 2218–24. <a target=xrefwindow id=d28576e4744 href="http://www.ncbi.nlm.nih.gov/pubmed/22344983">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4747 href="https://doi.org/10.1002/ibd.22917">Publisher Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d28576e4757 class=n-a></a>Florin TH, Paterson EW, Fowler EV, <i> et al.</i>: Clinically active Crohn's disease in the presence of a low C-reactive protein. <i>Scand J Gastroenterol.</i> 2006; <b>41</b>(3): 306–11. <a target=xrefwindow id=d28576e4768 href="http://www.ncbi.nlm.nih.gov/pubmed/16497618">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4771 href="https://doi.org/10.1080/00365520500217118">Publisher Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d28576e4780 class=n-a></a>Boyapati RK, Torres J, Palmela C, <i> et al.</i>: Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. <i>Cochrane Database Syst Rev.</i> 2018; <b>5</b>: CD012540. <a target=xrefwindow id=d28576e4791 href="http://www.ncbi.nlm.nih.gov/pubmed/29756637">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4794 href="https://doi.org/10.1002/14651858.CD012540.pub2">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4798 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6494506">Free Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14267228"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4807 class=n-a></a>Louis E, Mary JY, Vernier-Massouille G, <i> et al.</i>: Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. <i>Gastroenterology.</i> 2012; <b>142</b>(1): 63–70.e5. <a target=xrefwindow id=d28576e4818 href="http://www.ncbi.nlm.nih.gov/pubmed/21945953">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4821 href="https://doi.org/10.1053/j.gastro.2011.09.034">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14267228">F1000 Recommendation</a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d28576e4834 class=n-a></a>de Suray N, Salleron J, Vernier-Massouille G, <i> et al.</i>: 864 Close Monitoring of CRP and Fecal Calprotectin is Able to Predict Clinical Relapse in Patients With Crohn's Disease in Remission After Infliximab Withdrawal. a Sub-Analysis of the Stori Study. <i>Gastroenterology.</i> 2012; <b>142</b>(5): S-149. <a target=xrefwindow id=d28576e4845 href="https://doi.org/10.1016/S0016-5085(12)60560-5">Publisher Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732059051"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4854 class=n-a></a>Planell N, Masamunt MC, Leal RF, <i> et al.</i>: Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis. <i>J Crohns Colitis.</i> 2017; <b>11</b>(11): 1335–46. <a target=xrefwindow id=d28576e4865 href="http://www.ncbi.nlm.nih.gov/pubmed/28981629 ">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4868 href="https://doi.org/10.1093/ecco-jcc/jjx091">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4872 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5881703">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732059051">F1000 Recommendation</a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d28576e4885 class=n-a></a>Dierckx T, Verstockt B, Vermeire S, <i> et al.</i>: GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD. <i>J Crohns Colitis.</i> 2019; <b>13</b>(3): 389–94. <a target=xrefwindow id=d28576e4896 href="http://www.ncbi.nlm.nih.gov/pubmed/30312386 ">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4899 href="https://doi.org/10.1093/ecco-jcc/jjy162">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4903 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6434738">Free Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732635715"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4913 class=n-a></a>Dai C, Jiang M, Sun MJ, <i> et al.</i>: Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis. <i>J Gastroenterol Hepatol.</i> 2018; <b>33</b>(5): 990–7. <a target=xrefwindow id=d28576e4924 href="http://www.ncbi.nlm.nih.gov/pubmed/29427297">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4927 href="https://doi.org/10.1111/jgh.14121">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732635715">F1000 Recommendation</a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736820727"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4940 class=n-a></a>Hiraoka S, Inokuchi T, Nakarai A, <i> et al.</i>: Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis. <i>Gut Liver.</i> 2018; <b>12</b>(2): 142–8. <a target=xrefwindow id=d28576e4951 href="http://www.ncbi.nlm.nih.gov/pubmed/28873508">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4954 href="https://doi.org/10.5009/gnl17013">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4958 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5832338">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736820727">F1000 Recommendation</a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725850277"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d28576e4971 class=n-a></a>Lewis JD, Chen EZ, Baldassano RN, <i> et al.</i>: Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn's Disease. <i>Cell Host Microbe.</i> 2015; <b>18</b>(4): 489–500. <a target=xrefwindow id=d28576e4982 href="http://www.ncbi.nlm.nih.gov/pubmed/26468751">PubMed Abstract </a> | <a target=xrefwindow id=d28576e4985 href="https://doi.org/10.1016/j.chom.2015.09.008">Publisher Full Text </a> | <a target=xrefwindow id=d28576e4989 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4633303 ">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725850277">F1000 Recommendation</a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d28576e5002 class=n-a></a>Shaw KA, Bertha M, Hofmekler T, <i> et al.</i>: Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. <i>Genome Med.</i> 2016; <b>8</b>(1): 75. <a target=xrefwindow id=d28576e5013 href="http://www.ncbi.nlm.nih.gov/pubmed/27412252">PubMed Abstract </a> | <a target=xrefwindow id=d28576e5016 href="https://doi.org/10.1186/s13073-016-0331-y">Publisher Full Text </a> | <a target=xrefwindow id=d28576e5020 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4944441">Free Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d28576e5029 class=n-a></a>Sitapati A, Kim H, Berkovich B, <i> et al.</i>: Integrated precision medicine: the role of electronic health records in delivering personalized treatment. <i>Wiley Interdiscip Rev Syst Biol Med.</i> 2017; <b>9</b>(3). <a target=xrefwindow id=d28576e5040 href="http://www.ncbi.nlm.nih.gov/pubmed/28207198">PubMed Abstract </a> | <a target=xrefwindow id=d28576e5043 href="https://doi.org/10.1002/wsbm.1378">Publisher Full Text </a> | <a target=xrefwindow id=d28576e5047 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5400726 ">Free Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d28576e5056 class=n-a></a>Love-Koh J, Peel A, Rejon-Parrilla JC, <i> et al.</i>: The Future of Precision Medicine: Potential Impacts for Health Technology Assessment. <i>Pharmacoeconomics.</i> 2018; <b>36</b>(12): 1439–51. <a target=xrefwindow id=d28576e5067 href="http://www.ncbi.nlm.nih.gov/pubmed/30003435">PubMed Abstract </a> | <a target=xrefwindow id=d28576e5070 href="https://doi.org/10.1007/s40273-018-0686-6">Publisher Full Text </a> | <a target=xrefwindow id=d28576e5074 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6244622">Free Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d28576e5084 class=n-a></a>Waljee AK, Sauder K, Patel A, <i> et al.</i>: Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines. <i>J Crohns Colitis.</i> 2017; <b>11</b>(7): 801–10. <a target=xrefwindow id=d28576e5095 href="http://www.ncbi.nlm.nih.gov/pubmed/28333183">PubMed Abstract </a> | <a target=xrefwindow id=d28576e5098 href="https://doi.org/10.1093/ecco-jcc/jjx014">Publisher Full Text </a> | <a target=xrefwindow id=d28576e5102 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5881698">Free Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d28576e5111 class=n-a></a>Ashton JJ, Mossotto E, Ennis S, <i> et al.</i>: Personalising medicine in inflammatory bowel disease-current and future perspectives. <i>Transl Pediatr.</i> 2019; <b>8</b>(1): 56–69. <a target=xrefwindow id=d28576e5122 href="http://www.ncbi.nlm.nih.gov/pubmed/30881899">PubMed Abstract </a> | <a target=xrefwindow id=d28576e5125 href="https://doi.org/10.21037/tp.2018.12.03">Publisher Full Text </a> | <a target=xrefwindow id=d28576e5129 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6382508">Free Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d28576e5138 class=n-a></a>Parkes M, Noor NM, Dowling F, <i> et al.</i>: PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial. <i>BMJ Open.</i> 2018; <b>8</b>(12): e026767. <a target=xrefwindow id=d28576e5149 href="http://www.ncbi.nlm.nih.gov/pubmed/30523133">PubMed Abstract </a> | <a target=xrefwindow id=d28576e5152 href="https://doi.org/10.1136/bmjopen-2018-026767">Publisher Full Text </a> | <a target=xrefwindow id=d28576e5156 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6286485">Free Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a name=d28576e5165 class=n-a></a>Lee J, Biasci D, Noor N, <i> et al.</i>: OC-044 Profile trial: predicting outcomes for crohn’s disease using a molecular biomarker. <i>Gut.</i> 2017; <b>66</b>(Suppl 2): A22–A3. <a target=xrefwindow id=d28576e5176 href="https://doi.org/10.1136/gutjnl-2017-314472.44">Publisher Full Text </a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d28576e5185 class=n-a></a>Shen R, Olshen AB, Ladanyi M: Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. <i>Bioinformatics.</i> 2009; <b>25</b>(22): 2906–12. <a target=xrefwindow id=d28576e5193 href="http://www.ncbi.nlm.nih.gov/pubmed/19759197">PubMed Abstract </a> | <a target=xrefwindow id=d28576e5196 href="https://doi.org/10.1093/bioinformatics/btp543">Publisher Full Text </a> | <a target=xrefwindow id=d28576e5199 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2800366 ">Free Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d28576e5208 class=n-a></a>Shannon P, Markiel A, Ozier O, <i> et al.</i>: Cytoscape: a software environment for integrated models of biomolecular interaction networks. <i>Genome Res.</i> 2003; <b>13</b>(11): 2498–504. <a target=xrefwindow id=d28576e5219 href="http://www.ncbi.nlm.nih.gov/pubmed/14597658">PubMed Abstract </a> | <a target=xrefwindow id=d28576e5222 href="https://doi.org/10.1101/gr.1239303">Publisher Full Text </a> | <a target=xrefwindow id=d28576e5226 href="http://www.ncbi.nlm.nih.gov/pmc/articles/403769 ">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 28 Jan 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-54&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-54&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Gastroenterology, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK<br/> <sup>2</sup> Department of Gastroenterology, Monash Health, Clayton, Victoria, Australia<br/> <sup>3</sup> Faculty of Medicine, Nursing &amp; Health Sciences, Monash University, Clayton, Victoria, Australia<br/> <sup>4</sup> Translational Gastroenterology Unit, Nuffield Department of Medicine, Experimental Medicine Division, University of Oxford, John Radcliffe Hospital, Oxford, UK<br/> <sup>5</sup> Department of Gastroenterology, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA, UK<br/> <p> <div class=margin-bottom> Simon P. Borg-Bartolo <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Ray Kiran Boyapati <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Jack Satsangi <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> <div class=margin-bottom> Rahul Kalla <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-54/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 28 Jan 2020, 9:54 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.20928.1">https://doi.org/10.12688/f1000research.20928.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Borg-Bartolo SP <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=23032 data-id=20928 data-downloads="" data-views="" data-scholar="10.12688/f1000research.20928.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-54/v1/pdf?article_uuid=2df37b3e-f62b-4772-ab15-a0dfe5dd1704" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.20928.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Borg-Bartolo SP, Boyapati RK, Satsangi J and Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):54 (<a href="https://doi.org/10.12688/f1000research.20928.1" target=_blank>https://doi.org/10.12688/f1000research.20928.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=20928 id=mobile-track-article-signin-20928 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/20928?target=/articles/9-54"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=23032 /> <input name=articleId type=hidden value=20928 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Sunanda Kane</strong>, Division of Gastroenterology and Hepatology, Mayo Clinic, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Claudio Fiocchi</strong>, Department of Inflammation and Immunity, Lerner Research Institute, Department of Gastroenterology and Hepatology, Cleveland Clinic, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 28 Jan 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-54&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-54&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=62466-58676></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=62467-58677></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-54/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>28 Jan 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Sunanda Kane</strong>, Division of Gastroenterology and Hepatology, Mayo Clinic, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Claudio Fiocchi</strong>, Department of Inflammation and Immunity, Lerner Research Institute, Department of Gastroenterology and Hepatology, Cleveland Clinic, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-54&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-54/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Precision medicine in inflammatory bowel...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-54/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-54/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-54/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Borg-Bartolo SP et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-54/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-54",
            templates : {
                twitter : "Precision medicine in inflammatory bowel disease: concept, progress.... Borg-Bartolo SP et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-54/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Precision medicine in inflammatory bowel disease: concept, progress and challenges", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Precision medicine in inflammatory bowel disease: concept, progress and challenges", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/20928/23032")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "23032");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "58676": 0,
                           "58677": 1,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "d7626770-9539-410d-9bd3-f123ac1dbf27";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-54.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-54.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-54.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-54.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-54.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>